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I. INTRODUCTION 
 
1. Overweight and obesity 
Overweight and obesity are a complex multifactorial conditions characterized by excessive 
accumulation and storage of body fat, increasing the risk of disease and decreasing the quality 
of life. Both conditions are usually determined by the body mass index (BMI), defined as an 
individual’s weight in kilograms divided by the square of the height in meters (kg/m2).  
The World Health Organization (WHO) and National Institutes of Health defines overweight as 
having a BMI between 25 to 29.9 kg/m2; and obesity as BMI greater than or equal to 30 kg/m2 (1). 
Although BMI is a useful and easy measurement to assess overweight and obesity at a population 
level, it has several limitations (2). The most important limitation of this measure is that it 
doesn’t take into consideration the degree of fatness of individuals. Athletic individuals, normally 
with higher percentage of muscle mass, may have a higher than normal BMI and yet have a normal 
percentage of body fat. In addition, there are different obesity phenotypes according the fat 
mass distribution in the body. Central or upper body distribution (android) has been more 
correlated with an increased risk of disease (3–5) than general, peripheral or bottom (gynoid) 
distribution.    
 
1.1 Prevalence and trends of overweight and obesity 
Obesity has received a considerable attention as a major health problem and has reached 
epidemic proportion globally. This alarming increase affects both developed and developing 
countries throughout the world. At least 2.8 million people die as a consequence of being 
overweight or obese. 
 
In the last 25 years, worldwide obesity prevalence has doubled. In 2008, the WHO estimated that 
34% of men and 35% of women aged 20 or more were overweight; and 10% of men and 14% of 
women were obese (Figure 1). With the current trend, by 2030 up to 58% of the world’s adult 
population, approximately 3.3 million people, could be either overweight or obese (6). The 
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regions with highest prevalence of overweight and obesity were in the American and European 
regions (7). In the United States, 73 % of men and 66% of women have a BMI equal or greater than 
25 kg/m2. The prevalence in many European regions is also considerable, both northern (Germany 
and UK) and southern (i.e Spain and Greece). In UK, 66% of men and 58% of women could be 
considered overweight or obese (7). 
 
Figure 1 Worldwide age-standardized prevalence of overweight (upper) and obesity (lower) 
in adults 20 years and older by country in 2005. 
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In Spain, overweight and obesity rates are particularly alarming with and especial increase in the 
incidence of the disease during the last 25 years.  
 
Figure 2 Prevalence of overweight and obesity by age groups among Spanish men and women 
(8). 
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In 1987, 45% of men and 34% of the women had a BMI higher than 25 kg/m2. The most recent 
data extracted from the national health survey of 2011-2012 estimates that 63% of men and 44% 
of women have overweight or obesity (Figure 2) (9).  
 
Similar to adult, the prevalence in childhood obesity has been increased substantially over the 
last three decades (10). It has been estimated that 170 million children (aged less than 18 years) 
worldwide have overweight (11). An increase in BMI during childhood has also associated to 
serious health consequences and can be considered a risk factor for cardiovascular disease  (CVD), 
type 2 diabetes mellitus (T2DM) and cancer (12,13).  These diseases not also generate premature 
mortality, but also long-term morbidity. 
 
In USA, the prevalence of obesity has almost tripled among children and adolescents since 1980 
(14). This data indicates that childhood obesity is increasing even more rapidly than adult 
obesity, suggesting major problems for the population’s future health. A similar situation has 
been observed in Spain where nearly 30% of the children or adolescents are overweight or obese 
(9). Since 1987, the prevalence of overweight and obesity has increased 5% and 5,6% in boys and 
girls, respectively. 
 
1.2 Obesity risk factors 
Overweight and obesity are consequences of a disturbance in energy balance, when total energy 
intake (total amount of calories consumed) is higher than total energy expenditure (the 
combination of physical activity, basal metabolic rate and food thermogenesis). However, we 
still do not fully understand all underlying reasons of obesity because they are a complex mixture 
of genetic, environmental, psychosocial, cultural and cognitive factors. 
 
1.2.1 Non-Modifiable factors 
 
1.2.1.1 Genetic 
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Over the last 20 years, considerable strategies have been employed for the identification of 
genetic determinants of obesity, including studies of sever forms of obesity, genome wide linkage 
studies, candidate gene analyses and genome wide association studies. 
 
 During the eighties, twin and family studies suggested that 40-70% of the inter-individual 
variation in obesity risk and BMI can be attributed to genetic factors (15). Before 1995, the major 
attention in genetics of common obesity was candidate gene studies. Those studies were focused 
on genes with a suspected role in physiological pathways regarding body weight regulations and 
energy metabolism. One of the most studied is the melanocortin 4 receptor (MC4R) gene, widely 
expressed in the central nervous system. MC4R plays a key role in the regulation in food intake 
and energy metabolism. Functional mutations in MC4R are the commonest monogenic cause of 
sever early-onset obesity (16). However, in the past few years, genome wide association studies 
have led to breakthrough progress in the identification of obesity-susceptibly genes. To date, 
large-scale meta-analyses have identified 32 genetic loci associated with BMI, 14 loci associated 
with waist-to-hip ratio and 2 associated with percentage of body fat (17,18). Surprisingly, the 
combined effect of all-obesity associated variants is very modest and only explains 2% of the BMI 
heritability (19). The difference with the heritability of BMI estimated by twin and family studies 
(between 40% and 70%) could be partially explained by the modifying effects of environmental 
factors on genetic predisposition of obesity.      
 
1.2.1.2 Gender/age/ethnicity 
Gender, age and ethnicity are classical non-modifiable factors related to obesity. Gender 
differences in prevalence of overweight and obesity are no constant across regions or countries 
and sometimes are influenced by ethnicity and socioeconomic status.  
 
Generally, epidemiological studies show that men have higher overweight and obesity prevalence 
than women in the majority of regions and countries, but not all of them. In USA, the gender 
difference in the combined overweight and obesity was small, as the prevalence in men (67.0%) 
was slightly higher than in women (62.0%), while fewer men than women were obese, 27.7% vs. 
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34.0% (20). On the contrary, in Spain, the prevalence of overweight was 45.2% in men and 28.2% 
in women, whereas obesity rates for men and women were 18% and 16%, respectively (8).  
 
Significant age differences in the prevalence of overweight and obesity have been reported in 
various countries. In general, overweight and obesity prevalence is higher in adults than children 
in most countries. Part of the differences could be explained by the different diagnosis criteria 
used between children and adults (BMI vs. Age-sex-specific BMI percentiles), whereas others are 
actual differences due to age differences in physiology and health behaviors related to energy 
balance. Traditionally, prevalence of obesity has taken a “Λ” shape in relation to age. Several 
observational studies have found a gradual increase of obesity prevalence until 65 years of age, 
and a slightly decrease after that (21,22). Again, if we revise the data published in the last 
national health survey in Spain, similar trends were observed, although high obesity prevalence 
are carried around 75 years of age (9). 
 
Ethnic differences among overweight and obesity prevalence have also been reported (20,23). 
Studies conducted in US populations have shown large differences in obesity prevalence between 
ethnic groups, especially among women. Data from the US National Health and Nutrition 
Examination Survey (NHANES) indicate that the prevalence of obesity was 30.2, 42.3 and 53.9% 
in white, Mexican American and black women, respectively (20).      
 
  
1.2.2 Modifiable factors 
Despite the role of non-modifiable determinants on weight gain, the epidemic proportions in 
obesity worldwide over the last 25 years cannot be explained by gender, ethnicity or genetic 
factors alone. The obesity epidemic is a reflection of changes in lifestyle, which have been too 
fast for our genes to adapt to (24,25). The increasingly obesogenic environment we live in is 
characterized by sedentary lifestyles, increased portion sizes, an abundance of energy dense, 
nutrient-poor, palatable foods that encourage overconsumption.  
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1.2.2.1 Physical Activity 
Physical inactivity is one of the factors associated with the prevalence of overweight and obesity. 
A large cohort study in American nurses found that in 50,000 non-obese nurses, those who 
watched more television and had a sedentary lifestyle were at greater risk of developing obesity 
during 6 years of follow-up. The authors estimated that 30% (95%CI 24–36%) of new cases of 
obesity could be prevented by adopting a relatively active lifestyle (<10 h/week TV viewing and 
≥30 min of brisk walking per day) (26). Also, the results of a multicenter prospective cohort study 
conducted in 23 centers in 10 European countries including 405,819 healthy volunteers showed a 
strong inverse association between total physical activity and BMI and waist circumference. 
Changing to one level of physical activity to another (Inactive, moderately inactive, moderately 
active and active) corresponded to a difference of 1 cm in waist circumference and to a 
difference of 0.25 kg/m2 in the BMI (27). In the last 2011-2012 Spanish Health National Survey, 
59% of the participants performed light or no physical activity in the last seven days, and 35.9% 
of men and 46.6% of women declare themselves as sedentary (9). 
 
1.2.2.2 Tobacco    
Obesity and smoking are main causes of preventable morbidity and mortality around the globe 
(28). Smoking cessation have been associated with an increased risk of weight gain (29), due to 
a reduction in energy expenditure (30). However, the association between smoking and obesity 
is more complex. Several studies have found lower body weight and lower BMI among smokers 
than non-smokers (31). Smoking initiation in girls could be related to weight control (32), and 
among adult women, attempts for smoking cessation could be limited by fear of weight gain (33). 
In addition, smokers could also shear other obesity risk behaviors such as poor dietary habits and 
sedentary (34). 
 
1.2.2.3 Diet 
Several dietary factors have been associated with weight gain and a greater risk of obesity. 
Energy balance, food patterns and nutrient intake factors have been associated with body weight.  
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Energy density, obesogenic environment and food behaviors are determinants related to energy 
balance that the scientific community has focused their attention. Short term feeding trials have 
found that lower-energy dense food choices lead to a higher amount of food consumption but 
lower energy intakes compared to higher-energy density diets. An observational study, assessing 
whether dietary energy density predicts weight change over 6 y among a sample of non-Hispanic, 
white women, found that consumption of a lower-ED diet moderates weight gain. These results 
are supported by those observed in a randomized clinical trial (RCT) where 658 prehypertensive 
and hypertensive persons were randomly assigned to 1 of 3 groups: the established group received 
an intervention of 18 sessions implementing well-established hypertension recommendations, the 
established+Dietary Approaches to Stop Hypertension (DASH) group received an intervention of 
18 sessions also implementing the DASH diet, and the advice group received 1 session on these 
topics. Authors concluded that both large and modest energy density reductions were associated 
with weight loss and improved diet quality. This suggests that lower-energy density diets may 
lead to better appetite regulation and improved body weight control (35–37). In line with these 
results, some investigators have pointed out that portion size of foods as other contributing factor 
of weight gain. Current scientific evidence shows that the portion size of foods are related to 
the amount of food intake, and also to the perception of the individuals towards food (38). Other 
factors such skipping breakfast or snaking have also been associated with weight gain, however 
the results are controversial and inconsistent (39). 
The so-called obesogenic environment is also a determinant factor that contributes to increase 
the prevalence of obesity. The absence of supermarkets in local neighborhoods, principal source 
of vegetables and fruits, and long distance to supermarkets are associated with higher BMI (40–
42).  
 
Additionally, moderately strong evidence now indicates that some dietary patterns, including 
Mediterranean diet or Vegetarian diet, could play a role in the prevention of overweight and 
obesity (43,44). Mediterranean diet, characterized by a high intake of olive oil, fruit, nuts, 
vegetables, and cereals; a moderate intake of fish and poultry; a low intake of dairy products, 
red meat, processed meats, and sweets; and wine in moderation, consumed with meals, has been 
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inversely associated with BMI and obesity (45–54). The results of an observational study 
conducted in 3162 Spanish men and women aged 25–74 y showed that increasing adherence to 
the traditional Mediterranean dietary pattern reduced the obesity risk. Those individuals in the 
highest tertile of Mediterranean diet adherence had a 40% less risk to be obese than those in the 
lowest (47).  Vegetarian diet has also been proposed as a valid dietary pattern for the prevention 
of obesity. Several observational studies have evaluated the associations between vegetarian 
diet and BMI (44,55–58). All of them found that those individuals who followed a vegetarian diet 
had a lower BMI, than those who followed an omnivore diet. Rosell et al., conducted a 
prospective cohort study to evaluate 5-year changes in body weight among the participants of 
the EPIC-Oxford study. The authors categorized 21,966 healthy adults in 6 groups:  meat-eating, 
fish-eating, vegetarian, vegan, reverted and converted. Those who during the follow-up period 
had changed their diet in one or more steps in the direction vegan > vegetarian > fish-eater > 
meat-eater, were classified as 'reverted' and subjects who had changed their diet by one or more 
steps in the opposite direction were classified as 'converted'. Among those who did not change 
their diet, meat-eaters were those with more weight gain, whereas among those who changed 
their diet, converted had the lowest weight gain and reverted the highest (44). 
 
Finally, some nutrients and specific foods have also been associated with body weight. Dietary 
fat is the macronutrient with the highest energy content; however it exerts a weak satiating 
effect. Thus, it has been suggested that high-fat diets could be associated with weight gain due 
to the poor satiating effect of dietary fat that could lead to overconsumption. Evidence from 
epidemiologic studies linking fat intake to weight gain or obesity is weak (59–61) and inconsistent 
(62–68). The results from the Nurses' Health Study among 41,518 women reported weak positive 
associations between total fat intake and weight gain over 8 years, although there was a strong 
positive association with the percentage of energy from animal fat, saturated fat, and trans fat 
(69). On the contrary, Forouhi et al. didn’t found a significant association between the amount 
or type of dietary fat and subsequent weight change in 89,432 men and women from 6 cohorts 
of the European Prospective Investigation into Cancer and Nutrition study (70). 
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Dietary carbohydrates have also been associated with body weight and obesity. The majority of 
epidemiological studies evaluating the associations between carbohydrates intake and measures 
of overweight and obesity (BMI and waist circumference) have shown and inverse correlation (71–
82). Carbohydrate intake was found inversely associated with body weight gain in a cohort of 376 
Danish men and women (81). Higher carbohydrate intake was also associated with lower risk of 
obesity among 63,307 United States women in the Cancer Prevention Study II Nutrition Cohort 
(82).  
 
The role of dietary protein on body weight is highly controversial. Owing to the high satiating 
effect of dietary protein, it has been suggested that high-protein diets could be associated to a 
decreased energy intake. However, there is not sufficient evidence to support this theory (83–
89). Current scientific evidence suggests a differentiated role of dietary protein depending on 
the source (animal or vegetal). Kahn and coworkers evaluated changes in BMI and waist 
circumference in a cohort of 29,236 adults with a follow-up of 10 years. Increased BMI was 
positively associated with meat intake (89). In 2010, Vergnaud et al., evaluated the association 
between meat intake (red meat, poultry and processed meat) and weight gain in 270,348 women 
and 103,455 men during 5 years of follow-up. After controlling for potential confounders, the 
authors found a positive association between meat consumption and a higher BMI (88).  
 
Dietary fiber has been related with several health benefits, including body weight management 
by several mechanisms. Cross-sectional prospective studies have associated dietary fiber intake 
with a lower weight gain (90–92). This association has also been observed in longitudinal studies 
(93–97). Koh-Banerjee et al., showed that the increase in dietary fiber coming from fruit and 
whole-grain cereals was inversely associated with weight gain at long-term in a cohort of 27,082 
adult healthy men (97). 
 
Dietary glycemic index (GI) and glycemic load (GL) has also been associated with BMI and obesity, 
however it will be examined in a subsequent section. 
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1.3 Obesity as a risk factor 
Obesity is an important risk factor of hypertension, T2DM, dyslipidemia, CVD and some types of 
cancer (98) (98), increasing the risk of mortality and decreasing quality of life.  
 
1.3.1 Hypertension 
It is estimated that at least 75% of the incidence of hypertension is related directly to obesity 
(99). Experimental animal studies have demonstrated a consistent rise in blood pressure with 
excess weight gain induced by prolonged high fat diet (100,101). Epidemiological data 
unequivocally support the link between body weight and BP. Data from the NHANES indicates 
that the prevalence of hypertension among obese individuals was 42.5% compared with the 27.8% 
for overweight individuals and 15.3% for those with normal BMI (102). Additionally, higher BMI is 
also associated with greater risk of having hypertension. In the Framingham Heart Study, 
compared to those individuals with normoweight, the relative risk of developing hypertension in 
long-term follow-up were 1.48 and 1.70 for overweight men and women and 2.23 and 2.63 for 
obese men and women, respectively (103). Clinical studies also suggest that excess weight gain 
is a key contributor to elevated blood pressure in most patients with primary hypertension. 
Weight loss between 5%-10% decreases blood pressure in normotensive as well as in hypertensive 
obese subjects and reduces the need for antihypertensive medication (104).  
Mechanisms underlying the link between obesity and hypertension include the renin-angiotensin-
aldosterone system , the sympathetic nervous system (SNS), metabolic dysregulation (including 
hyperinsulinemia, adipokine imbalance, and increased inflammatory cytokines). Activation of 
renin-angiotensin-aldosterone system system thought basically the SNS is a major factor of the 
obesity-related hypertension (105). Insulin and Leptin, both increased in individuals with obesity 
(106), have also found to activate the SNS (107) and, therefore, contribute to obesity-related 
hypertension. I addition, insulin has direct effect on sodium retention in the kidney (108). 
Another contributing factor in obesity-associated hypertension is vascular stiffness which is 
influenced by adipokines such as leptin and hyperinsulinemia (109). 
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1.3.2 Type 2 diabetes mellitus 
The prevalence of T2DM and Obesity are both increasing exponentially. Evidence from 
epidemiological studies show that obesity and weight gain are associated with an increased risk 
of diabetes (110,111). BMI, waist circumference and hip-to-waist ratio are anthropometric 
measurements used as risk indicators for T2DM (112,113). Recently, a meta-analysis of 15 
prospective studies has found that waist circumference and waist-to-hip ratio (markers of 
abdominal obesity or visceral fat) could be better indicators of T2DM risk than BMI (marker of 
general obesity) (114).  
Obesity-induced T2D has been recognized as an inflammatory disease. The systemic low-grade 
inflammatory response that is often observed in obesity detrimentally affects both insulin 
signaling and beta-cell function and may thus contribute to the development of T2D (115–117). 
 
1.3.3 Cardiovascular Disease 
Cardiovascular disease is caused by disorders of the heart and blood vessels, and includes 
coronary heart disease (myocardial infraction), cerebrovascular disease (stroke), raised blood 
pressure (hypertension), peripheral artery disease, rheumatic heart disease, congenital heart 
disease and heart failure. Now a days, CVD are the leading cause of mortality in developed 
countries (118) and it is estimated that it will increase, especially in low and middle income 
countries (119). 
 
As stated before, obesity is a precursor of hypertension, diabetes and their associated risks, and, 
therefore a risk for CVD. Epidemiological evidence have shown a positive association between 
overweight and obesity, and coronary heart disease (CHD) and stroke (120–122). Data from a 
meta-analysis including 21 cohort studies with more than 300,000 participants showed a 
significant increased risk of CHD independently of traditional risk factors (blood pressure and 
cholesterol concentrations). Relative Risk (RR)s (95% CI) for moderate overweight and obesity 
compared with normal weight were 1.32 (1.24-1.40) and 1.81 (1.56-2.10), respectively (122). In 
case of stroke, another meta-analysis of prospective studies with 2 million participants showed 
significant direct and graded association between excessive body weight and ischemic stroke. 
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After adjusting for potential confounders, RR (95% CI) for ischemic stroke was 1.22 (1.05–1.41) 
for overweight and 1.64 (1.36–1.99) for obesity (120).  
 
1.3.4 Cancer 
Epidemiological estimations shows that 20% of all cancers are caused by excessive body weight 
(123). In postmenopausal women, in particular, approximately 50% of all cancers can be 
attributed to obesity (124). Many prospective epidemiological studies have demonstrated a 
positive association between overweight and cancer, even though obesity alone does not 
apparently heighten cancer risk in all tissues by the same amount (12,123–128). 
 
A recent systematic review and meta-analysis of prospective observational studies, with 282,000 
incident cancer cases and a follow-up greater than 133 million person-years, has demonstrated 
that the obesity and cancer association is sex specific over a wide range of malignancies, and 
this remains mostly true for different geographic populations (125). 
 
The reports of international agencies for cancer research have showed that most common types 
of cancer in obese individuals are endometrial, esophageal adenocarcinoma, colorectal, 
postmenopausal breast, prostate, and renal (12,128). 
 
Apart of from BMI, other anthropometrical measurements including waist circumference or waist-
to-hip ratio have been investigated as adiposity indicators of cancer risk. Several cancers, such 
as colon, premenopausal breast, endometrium, and esophageal adenocarcinoma, together with 
pancreas tumors, have been more associated with abdominal obesity than BMI (129–133). 
Due to the great variety of cancers associated with abdominal and general obesity, the list of 
possible mechanisms linking both pathologies is also extensive. Lifestyle, genetic and molecular 
factors have been related obesity to cancer (134–141). 
 
2. Metabolic Syndrome 
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2.1 Pathology and diagnose 
The metabolic syndrome (MetS) was used, simultaneously, for the first time at the end of the 
seventies by Haller (142) and Singer (143) to describe different combinations of metabolic 
disorders such as central obesity, diabetes mellitus, hyperlipoproteinemia, hyperuricemia, 
hepatic steatosis, gout and hypertension. In 1988, this concept, also called insulin resistance 
syndrome (144), was unified by Reaven (145), although obesity was not present in this definition. 
Now a day, the MetS is defined as a cluster of several cardiometabolic risk factors including 
central obesity, hyperglycemia, hypertension and atherogenic dyslipidemia. This term was 
officially institutionalized by the WHO (146) and the Third Report of the National Cholesterol 
Education Program’s Adult Treatment Panel (ATP III) (147,148). Additionally, similar, but not 
equal, definitions were described by other institutions (149–151).  
 
In 2009, an unique definition was established by the International Diabetes Federation and 
American Heart Association/ National Heart, Lung, and Blood Institute (152). They agreed that 
the presence of any 3 of the 5 risk factors constitutes a diagnosis of MetS. In Table 1 are shown 
the 5 criteria used for its definition. 
 
Table 1 Criteria for Clinical Diagnosis of the Metabolic Syndrome(152). 
Measure Categorical Cut Points 
Abdominal Obesity Population- and country-specific definitions 
Elevated triglycerides ≥150 mg/dL (1.7 mmol/L) or drug treatment 
Reduced HDL-C 
<40 mg/dL (1.0 mmol/L) in males; <50 mg/dL 
(1.3 mmol/L) in females or drug treatment 
Elevated blood pressure 
Systolic pressure ≥130 mmHg and/or diastolic 
pressure ≥85 mmHg or drug treatment 
Elevated fasting glucose ≥100 mg/dL or drug treatment 
 
2.2 Prevalence and trends of Metabolic Syndrome 
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Like the obesity epidemic, the MetS has become one of the major health problems worldwide. It 
is estimated that the prevalence of the MetS among worldwide adult individuals is reaching 25% 
of the population (153–156).  
In the U.S., approximately one-fifth of the adult population is at high cardiovascular risk 
(154,155). Data from the NHANES indicates that, between 2009 and 2010, the age-adjusted 
prevalence of MetS in adult population was 22.9% (95% CI: 20.3% to 25.5%). The same authors 
found a slightly decrease in the prevalence of the MetS between 1999 [25.5% (95% CI: 22.5% to 
28.6%)] and 2010 [22.9% (95% CI: 20.3% to 25.5%)] due to a decrease in hypertriglyceridemia 
prevalence (33.5% to 24.3%), as did elevated blood pressure (32.3% to 24.0%) (155). They suggest 
that the decrease in hypertriglyceridemia and hypertension is correlated with an increase in in 
lipid-modifying and anti-hypertensive drugs, respectively.  
 
Similar situations have been observed in several European countries. A study with 11 European 
and one US population-based cohorts found that almost 25% of the adult population had MetS. 
They also found that the prevalence increased with advanced age, from 3.7 with age between 
20 and 29 years to over 30% with age 70 years or more. 
 
Figure 3 Prevalence of metabolic syndrome in the periods 1992–1993 and 2002–2003 (157). 
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Countries with a higher prevalence of MetS were Lithuania (>60%), Greece (40%) and Spain (40%), 
whereas those with lower prevalence were Italy (Sardinia) (<10%), Sweden (>10%) and Belgium 
(<20%). In the Mediterranean population of Catalonia, Spain, the prevalence of MetS between 
1992 and 1993 were 18.4% (95% CI 15.8–21.1%) using the ATPIII criteria and 25% (95% CI 22.0–
28.0%) with IDF. After 10 years, the prevalence had increased a 6.4% when ATPIII criteria were 
used and a 3.5% when IDF criteria were used (Figure 3) (157).   
 
2.3 Metabolic Syndrome as a cardiovascular risk factor    
As stated before, the MetS is a cluster of CVD risk factors and therefore, it is reasonable to thing 
that those individuals with MetS could be more exposed to develop CVD. Many studies have 
evaluated the associations of prevalence of MetS and risk of CVD (158–165).  
 
In a recent meta-analysis of 87 prospective observational studies which included nearly one 
million men and women with a mean follow-up of ranging from 1.0 to 32.7 years, Mottillo et al. 
investigated the associations of MetS and risk of CVD, CVD mortality, stroke, myocardial 
infarction and all-cause mortality (158). They found that the MetS was associated with and 
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increased risk of CVD (relative risk [RR]: 2.35; 95% CI: 2.02 to 2.73), CVD mortality (RR: 2.40; 95% 
CI: 1.87 to 3.08), all-cause mortality (RR: 1.58; 95% CI: 1.39 to 1.78), myocardial infarction (RR: 
1.99; 95% CI: 1.61 to 2.46), and stroke (RR: 2.27; 95% CI: 1.80 to 2.85).  They also found that RR 
for all estimates of cardiovascular risk was slightly higher in women than men, especially in all-
cause mortality.  
 
The pathophysiological mechanisms linking the MetS with an increased risk of CVD is still unknown 
(152). However, it is largely accepted by the scientific community that insulin resistance is an 
underling process of the MetS. Insulin resistance, represented by hyperinsulinemia and 
hyperglycemia, lead to the activation of the sympathetic nervous system triggering sodium 
retention and volume expansion and, thus, higher BP (166,167). Also, hepatic production of very 
low-density lipoproteins is increased in those individuals with insulin resistance, leading to 
hypertriglyceridemia, low High Densisty Lipoprotein (HDL) cholesterol, elevated apolipoprotein 
B, elevated small Low Density Lipoprotein (LDL) cholesterol, and consequently, atherosclerosis 
(168–170).   
 
3. Treatment of Obesity and Metabolic Syndrome  
The main goals of Obesity and MetS treatment include sustained weight loss with a primary focus 
on abdominal obesity, improvement of obesity-related health risks and quality of life, and 
reduction of mortality. Intentional weight loss normally is associated with reduced mortality, 
improved blood pressure and lipid profile, mental health and quality of life (171). A modest 
weight loss of 5-10% significantly reduces obesity-related risks (171,172).   
 
Mainly, there are three strategies for obesity treatment. Bariatric surgery can be considered for 
patients with more severe disease and who meet its indications. Pharmacotherapy may be useful 
in some individuals for whom non-pharmacological approaches alone are ineffective or 
insufficient. However, lifestyle management, including diet and physical activity, is 
recommended as the first-line treatment for obesity and its metabolic consequences. 
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3.1 Surgical treatment 
The International Federation of Surgical Obesity has in consideration several selection criteria 
which make a patient suitable for bariatric of weight-loss surgery. Patients must have a BMI ≥ 40 
kg/m2 or those with a BMI ≥ 35 kg/m2 who have associated high-risk comorbid conditions such as 
atherogenic diseases, or T2DM; reasonable attempts at other weight loss techniques; age 
between 18-65 years; obesity related health problems; no psychiatric or drug dependency 
problems; a capacity to understand the risks and commitment associated with the surgery and 
pregnancy not anticipated in the first two years following surgery.  
 
Traditionally, bariatric surgery has been classified in three categories based on anatomical 
changes, restrictive, restrictive-malabsorptive and malabsorptive. However, clinical benefits of 
bariatric surgery in weight loss and improving metabolic comorbidities have been attributed to 
changes in the physiological responses of gut hormones and adipose tissue metabolism (173,174). 
The most common techniques performed in bariatric surgery are Laparoscopic Adjustable Gastric 
Banding, Laparoscopic Sleeve Gastrectomy and Roux-en-Y Bypass. Mean percent weight loss is 
estimated to be between 25% to 95% of total excess weight, depending on the procedure (175).   
 
Several studies have demonstrated a decrease in co-morbid conditions and improvement in health 
after surgery for obesity (176–178). Data from the Swedish Obese Subjects study showed a 
decrease in prevalence of cancer and a 28% reduction in the adjusted all-cause mortality rate in 
those subjects in the surgical group compared with conventionally treated obese  (177,178). Data 
from 7,925 patients of the Utah study also supports these results showing a 52% lower rate of 
death from all-causes (176). 
 
3.2. Pharmacological treatment  
Improving diet combined with reinforced physical activity constitutes the first-line management 
for overweight or obesity, but adherence to lifestyle measures is difficult to achieve. Individuals 
who cannot achieve significant weight loss by lifestyle interventions alone may benefit from 
pharmacological agents which promote weight loss.  
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Weight loss medications have been classified in two major categories: appetite suppressants and 
gastrointestinal fat blockers. Appetite suppressing medications have targeted three monoamine 
receptor systems in the hypothalamus: noradrenergic, dopaminergic and serotonergic (179). In 
the other hand, Orlistat is a potent slowly reversible inhibitor of pancreatic, gastric, and 
carboxylester lipases and phospholipase A2, which are required for the hydrolysis of dietary fat 
in the gastrointestinal tract into fatty acids and monoacylglycerols (180).  
 
Orlistat, lorcaserin, and phentermine plus topiramate-ER, the most used weight-loss drugs at this 
time, increases the chances to achive a >5% of weight loss after 1 year when are used in 
conjunction with lifestyle intervention (181). However, in Spain, Orlistat is the only accepted 
pharmacological treatment for obesity.  
 
3.3. Lifestyle modification  
The key element of obesity treatment is assisting patients to develop healthy lifestyle habits 
through the improvement of better dietary and physical activity choices that will lead to a 
gradual weight loss. The initial goal is to achieve a 5% to 10% weight loss over the initial 6 months 
of treatment (182). Caloric restriction is the most important component in achieving weight loss, 
focusing in fat mass, whereas increased and sustained physical activity is particularly important 
in maintaining the lost weight and reducing the loss of fat free mass (183–185).  
 
3.3.1 Physical activity  
It has been well established that weight control is a delicate balance between energy intake and 
energy expenditure, of which energy physical activity is the most variable and modifiable 
component of the energy expenditure side of the energy balance equation. Physical activity is 
ranged between 10% and 40% of total daily energy expenditure and thus plays an important role 
in the treatment of overweight and obesity (186). The American College of Sports Medicine 
recommends 150 to 250 minutes per week to prevent weight gain(187) and 225 to 420 to promote 
clinically significant weight loss (183).  
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Epidemiological data suggest that physical activity is a key element in weight gain (186,188–190). 
Data from 9325 individuals of NHANES showed that low levels of self-reported recreational 
physical activity were associated with a 3-fold and 5-fold increased risk of weight gain in men 
and women, respectively (191).  
 
However, the results obtained from studies investigating weight loss as a result of aerobic 
exercise training are very heterogonous. The Dose Response to Exercise in Women study found 
no significant changes in body weight in 464 postmenopausal women exercising at 50% (− 0.4 kg), 
100% (− 2.2 kg) and 150% (− 0.6 kg) of public health guidelines for 6 months despite greater than 
89% adherence in all ET groups. Also, the Inflammation and Exercise study (n=129) observed no 
significant weight loss after 4 moth of exercise training (-0.4 kg) compared with the control group 
(0.1 kg) (192). On the contrary, the Diabetes Aerobic and Resistance Exercise study showed 
significant weight loss in the exercise training group (-0.74 kg) compared to the control group 
after 22 weeks of intervention in 251 adults with T2DM.  
 
Although approximately >2 kg can be achieved by exercise training alone, most studies of short-
term weight loss interventions show that the most significant weight loss occurs when a 
combination of diet and exercise is used (183,193–195).         
 
3.3.2 Diet 
Dietary treatment of obesity has as a primary objective to achieve a sustained weight loss which 
allows decreasing obesity-related risks to health. During the last decades, numerous attempts 
have been done to deal with obesity.  
 
The majority of the international societies studying obesity recommend low-energy diets as the 
most valid approximation to obesity treatment (196–204). Although low-energy diet has not a 
specific definition, scientific community and health professionals have established low-energy 
diets as diets with a reduction between 500 and 1000 kcal/d of daily calorie needs and with a 
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total energy intake greater than 800 kcal/d. Macronutrient composition of the low-calorie diet 
(LCD) is still a matter of debate, although a standard composition for a well balance diet has 
been proposed (Table 2) (197).  The use of this type of diets, with a treatment period between 
6 and 12 months, has been associated with a mean loss of about 8%, although, with longer periods 
(3-4.5 years), the loss decreases to about 4% (205). To achieve the calorie reduction, several 
strategies have been proposed including low energy density foods, meal replacements and 
portion size.  
 
Some studies have evaluated the effect of energy density of foods as obesity treatment (206–
209). Ello et al. conducted a 1-year randomized controlled trial to evaluate the effect on weight 
loss of 2 strategies, one low-fat group and one low-fat group + low energy density foods, for 
reducing the energy density of the diet. After one year, both groups had significant weight loss, 
although low energy density foods group had significantly higher loss (209). 
 
 Table 2 Recommended macronutrient composition for treatment of obesity(197). 
Energy Percentage 
Carbohydrates 45-55% 
Proteins 15-25% 
Lipids 23-35% 
Saturated Fatty acids <7% 
Monounsaturated Fatty acids 15-20% 
Polyunsaturated Fatty acids <7% 
Trans Fatty acids <2% 
Fiber 20-40g 
 
One of the most important factors which affect weight-loss diets is the treatment adherence. A 
suggested strategy to facilitate diet adherence has been to use meals replacements. Meal 
replacements products have also been shown to improve weight loss (210,211). In 2003, 
Heymsfield et al, conducted a meta-analysis including 6 randomized controlled clinical trials with 
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487 participants and a follow-up between 3 and 51 months.  A significant higher weight loss was 
observed in the group using meal replacements (7% loss of the initial body weight) than the 
control group (4% loss of the initial body weight). Meal replacement has also been investigated 
as nutritional strategy for weight maintenance. A randomized controlled trial was conducted to 
assess the long-term effects of 2 energy-restricted diets on weight loss in 100 participants. During 
the first 3 months, one of the intervention groups replaced 2 of the 3 meals with meal-
replacement shakes, soups or hot chocolate. During this initial phase, the meal-replacement 
group lost 11.3+/-6.8%, whereas the control group lost  5.9+/-5.0% (210). In a second phase of 
the same study, both groups were prescribed the same energy-restricted diet with one meal and 
one snack replacement for an additional 4 year to maintain the weight loss. At the end of follow 
up, both groups maintained the initial weight loss and average weight loss of meal-replacement 
group was consistently greater than control group (p = 0.001).  
 
Portion size is an important determinant of energy intake. The number of calories ingested by 
subjects at a meal has been directly correlated with the serving size offered (212,213). A 6-
month clinical trial evaluating the effect of portion size vs. usual care in 130 obese individuals 
found that those individuals in the intervention group loss more weight than those in the control 
group (mean ± SD, 1.8% ± 3.9% vs 0.1% ± 3.0%, P = .006) (214).  Larger studies are needed to 
assess the utility of portion size tools in obesity treatment. 
 
A similar approximation to low-energy diets are very-low-calorie diets (VLCD). VLCD are 
commercially formula foods, providing about 450–800 kcal/d, replacing all meals and snacks. The 
use of this type of diets are reserved for patients with severe obesity (BMI ≥ 30 kg/m2) (215) and 
should only be used for fewer than 16 weeks because of clinical adverse effects (216). Scientific 
evidence regarding VLCD suggest that this type of diets is not more effective at long-term than 
conventional low-calorie diet (203). The majority of the studies found that participants who 
completed a comprehensive VLCD program (that included lifestyle modification) generally lost 
15% to 25% of initial weight in 3 to 4 months (217–223) in comparison to the 8% achieved with the 
LCD. In a meta-analysis of 6 RCT including 425 morbidly obese participants with a follow-up 
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between 6 to 26 months, Tsai et al. found that, compared with the LCD, VLCD generated a higher 
short-term weight loss (9.7± 2.4% vs. 16.1±1.6%, respectively; P = 0.0001), although similar long-
term weight losses were found between the two type of interventions (5.0 ± 4.0% vs. 6.3 ± 3.2%, 
respectively; P > 0.2) (223). 
 
Calorie restriction can achieve a moderate amount of weight loss in a short term basis, but often 
this dietary induced weight-loss cannot be maintained long term (205). A large number of dietary 
strategies with different proportions of lipids, proteins, and carbohydrates are currently being 
investigated. There is an intense debate about the different diets and macronutrient proportions 
that are most effective for treating overweight or obesity. Several trials assessing dietary 
composition have been conducted to improve both weight loss and weight maintenance.  
 
3.3.2.1 Low-fat diets  
Over the last 30 years, high-carbohydrate, low-fat diets are recommended as ‘healthy’ for the 
population in general (224) as well as for individuals susceptible to heart disease (225), cancer 
(226), hypertension (225,227), and diabetes (228). Traditionally, low-fat diets have been the 
primary approach of the dietary intervention for obesity treatment (197,201,202,204). There are 
several reasons for targeting dietary fat intake (229,230). Compared with carbohydrates and 
proteins, fat is the most concentrated source of energy, providing ≈38 kJ g–1 as opposed to 17 kJ 
g–1 for carbohydrate or protein, and is preferentially stored in adipose tissue (231). High-fat foods 
are relatively less satiating than are isoenergetic portions of high-carbohydrate or high-protein 
foods; thus individuals on a high-fat diet would tend to consume more total energy to gain the 
required amount of carbohydrate as someone on a low-fat diet (232). Furthermore, the improved 
taste and palatability of fatty foods increase the potential for active overconsumption.  
 
Several clinical trials have evaluated the effect of energy-restricted low-fat diets on weight loss. 
A multicentric intervention trial evaluated whether an energy-restricted low-fat diet (25%) was 
superior to an energy-restricted moderate high-fat diet (40%) for the treatment of obesity. At 
the end of the intervention, average weight loss was 6.9 kg in the low-fat group and 6.6 kg in the 
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high-fat group (p>0.05). However, more subjects lost >10% in the low-fat group than in the high-
fat group ((20.8%, n = 70) versus (14.7%, n = 46) (P = 0.02) (233). Powell et al conducted a clinical 
trial with thirty-five obese women 25 to 45 years of age where randomly allocated into one of 
four energy- restricted dietary fat groups, with 10%, 20%, 30%, or 40% of caloric intake as dietary 
fat. After 12 weeks, no significant differences in the rate or amount of body weight or percent 
body fat lost across the four groups (234). 
 
3. 3.2.2 Hyperproteic diets   
Now a days, hyperproteic diets, based on carbohydrates substitution for protein, has become a 
popular alternative due to the potential benefits for obesity treatment. Traditionally, dietary 
recommendations for protein intake has been established around 10-15% of the total energy 
intake, however, the protein intake of actual hyperproteic diets is around 20-30%. Among the 
most popular hyperproteic diets there are the Atkins diet, the Zone diet and most lately the 
Dukan diet. Although these type of diets have become extremely popular among general 
population, scientific community have not yet reach a clear opinion either hyperproteic diets are 
a good alternative for body weight or not.  
 
Short-term clinical trials assessing the effect of high-protein intake have found a modest positive 
effect on weight loss, although this beneficial effect is not sustained in a long term basis (197). 
A recent meta-analysis of 24 RCT evaluated energy-restricted, isocaloric, high-protein, low-fat 
diets with standard-protein, low-fat diets on weight loss, body composition, resting energy 
expenditure, satiety and appetite, and cardiometabolic risk factors. The authors found a 
moderate beneficial effect of high-protein, low-fat diets on weight loss at short-term on 
comparison of standard-protein, low-fat diets [mean difference, 95% CI: -0.79 kg (-1.50, -0.08), 
P=0.03, respectively). Also, in comparison to standard-protein, low-fat diets, high-protein, low-
fat diets had greater reductions in fat mass (−0.87 kg; 95% CI: −1.26, −0.48 kg), in fat-free mass 
(0.43 kg; 95% CI: 0.09, 0.78 kg) and resting energy expenditure (595.5 kJ/d; 95% CI: 67.0, 1124.1 
kJ/d) (235). Despite the moderate beneficial effects at short-term, RCT comparing high-protein 
diets vs. standard diets didn’t achieve to replicate the same results at long-term (236–242). Only 
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the study of Gardner et al. compering 4 different diets (Atkins, Zone, Ornish y LEARN) found 
significant greater body weight reductions among those in the Atkins diet (low-carbohydrates and 
a 27% of protein content) than the rest of intervention diets (243). However, the study was only 
conducted in women (n=311) and the rest of the intervention diets were not traditional high-
carbohydrates diets but different popular diets. 
 
One of the major concerns about high-protein diets was their long-term safety (244). In 2007 two 
prospective observational studies were published evaluating the associations of protein 
consumption and cardiovascular and all-cause mortality. The first study was conducted in 42,237 
Swedish women, with a mean follow-up of 12 years, where those individuals with higher protein 
and lower carbohydrate intakes had a 37% more risk of cardiovascular death and an 11% more 
risk of all-cause mortality (245). Similarly, the authors of the second study, conducted in 22,944 
Greek adults (mean follow-up of 10 years), found that also those participants in with higher 
intake of carbohydrates and protein had an increased risk of all-cause mortality (per 5 units, HR: 
1.22; 95% CI 1.09 to 1.36) (85). However, some authors suggests that protein source could be a 
key element in the associations between protein intake and mortality (84,246).  
 
3.3.2 3 Low-fat vs. Low-carbohydrate diets 
Although international institutions and public health guidelines promote high carbohydrates, low 
fat, energy-restricted diets as the first option for obesity treatment, the persistence of obesity 
epidemic have been increasing for the last decades and new dietary strategies have to be 
evaluated to overcome this epidemic.  
 
Low-carbohydrates diets have been proposed as a valid alternative to low fat-diets. The logic 
explanation to carbohydrate restriction is that, in response to postprandial hyperglycemia, 
changes in regulatory hormones, insulin and glucagon, will increase fat oxidation and decrease 
fat storage.  
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A great number of trials and several meta-analyses have compared the effects of low-fat diets 
vs. low-carbohydrates diets on weight loss (247–250). In 2006, two similar meta-analyses of RCT 
were published comparing  the effects of low-carbohydrates diets vs. low fat diets (248,249). 
First, Nordmann et al. published a meta-analysis of 5 RCT compering low-carbohydrates diet 
without caloric restriction vs. energy-restricted low-fat diets. The results showed that low-
carbohydrates diets exert a greater weight loss than low-fat diets during the first 6 months, 
although this effect was not significant at 12 month. Similar results were found in another meta-
analysis of 6 RCT conducted by Levine and coworkers. The authors conclude that low-
carbohydrates diets resulted in a higher weight loss than low-fat at 6 months       
     
4. Glycemic index and glycemic load 
 
4.1 Glycemic index 
The concept of the GI was derived from the dietary fiber hypothesis proposed by Burkitt and 
Trowell, who suggested that foods with a slow absorption rate could have better metabolic 
benefits in relation to western societies’ diseases such diabetes and coronary heart disease (251). 
The origin of the GI concept was to establish a valid and robust measure to calculate the impact 
of the carbohydrates present in foods on blood glucose concentrations. In 1981,Prof David Jenkins 
and coauthors defined the GI concept as the incremental area under the blood glucose response 
curve of a 50g carbohydrate portion of a test food expressed as a percent of the response to the 
same amount of carbohydrate from a standard food taken by the same subject (252). Thus, the 
GI is a property of the carbohydrates present in the foods, and it’s determined by several factors 
including the nature of the monosaccharide forming the carbohydrates, the amount of 
carbohydrates absorbed and the amount that are metabolized. The methodology for GI 
calculation is recognized and described by the International Standards Organization (26 642:2010) 
and by the Food and Agriculture Organization of the United Nations (253). Intrinsic and extrinsic 
factors that alter the rate of gastrointestinal motility, digestion and absorption, and the nature 
of the starch, cooking method, particle size, and the presence of fiber, fat, and proteins were 
all found to result in differences in the GI (254,255). Although the glycemic response generated 
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by these foods could differ between individuals with different metabolic conditions, the GI of 
foods is very similar regardless of the pathophysiological condition of the individuals (256). The 
GI of a diet can be calculated through the individual GI values of the foods composing the whole 
diet, and it can estimate the quality of the dietary carbohydrates regardless of the amount 
consumed (257). 
 
Due to glycemic responses generated by carbohydrates are strongly related to insulin responses 
(258,259), GI has been investigated as a possible tool for the prevention or treatment of chronic 
diseases (260–262). GI was firstly used as a dietary tool to T2DM management, however 
subsequent studies have associated GI with other chronic diseases such CVDs, cancer and obesity 
with inconsistent results.  
 
Several investigators have suggested that hyperglycemia generated by high-GI diets can be a key 
dietary factor in the pathogenesis of the T2DM. Prospective cohort studies have found strong 
positive associations between GI and risk of T2DM incidence (263–267). A recent meta-analysis of 
21 prospective cohort studies has evaluated a systematic literature review and dose-response 
meta-analysis of evidence from prospective cohorts. The results of this recent meta-analyses 
indicated significant a dose-response RR for GI (1.08 per 5 GI units; 95%CI: 1.02 to 1.15) (268). 
 
Also, several RCT have evaluated the effect of dietary GI as a dietary approach to the treatment 
of T2DM. Ajala et al. published a systematic review and a doses-response meta-analysis of RCT 
evaluating the effect of GI on the overall strategy of diabetes management.  Beneficial effects 
on glycated hemoglobin was found on those individuals allocated in a low-GI versus other diets 
(high-GI, high fibre or American Diabetes Association recomendations) (Mean difference: -0.14; 
95%CI: -0.24, -0.03, respectively) (269).     
 
Postprandial state has been recognized as a key point on the development of cardiovascular risk 
factors. Elevated postprandial glycemia and insulinema present after the consumption of high-GI 
foods are two important risk factors associated with MetS (270–274). In this context, the use of 
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GI have also been explored as a dietary alternative to reduce the carbohydrate absorption rate, 
and hence to treat CVD. Two independent meta-analyses of 28 RCTs with a follow-up between 4 
and 78 weeks have shown a beneficial effect of low-GI vs. high-GI on total cholesterol and LDL 
(275,276). However, these results were not supported by the data of another recent meta-
analysis of 14 RCTs with a follow-up greater than 6 month where no effect was found between 
interventions with different GI and blood lipids. However, the authors reported a beneficial 
effect of low-GI interventions in C-reactive protein (CRP) and insulin concentrations (277). 
 
In this context, observational studies have associated high dietary GI with an increased risk of 
coronary heart disease and stroke. Four different meta-analyses of observational studies have 
assessed the link between GI on CVD risk and have found similar results (278–281). The most 
recent and more extensive of them found 26% increased risk of CHD in women, but not in men, 
allocated in the highest quartile of dietary GI in comparison with those in the lowest. Similar 
results were found when stroke was the main outcome, although in this case increased risk was 
associated in both men and women (278).         
 
Several investigators have suggested that metabolic effects generated after the consumption of 
high GI food could be associated with an increased risk of several types of cancer (282–288). In 
particular, hyperinsulinemia have been pointed as the unifying mechanism for the developing of 
several types of cancer (289,290). Observational studies evaluating the associations of GI and 
cancer have found different results depending on the type of cancer. A recent meta-analysis 
evaluating diabetes-related cancers (bladder, breast, colon–rectum, endometrium, liver and 
pancreas) found a pooled RR (95 % CI) of diabetes-related cancers of 1.07 (1.04, 1.11) in a 
comparison of the highest and lowest categories of GI. In an specific analysis of cancer type, only 
increased risk of breast cancer (RR 1.06; 95 % CI 1.02, 1.11) and colorectal cancer (RR 1·08; 95 
% CI 1·00, 1·17) was associated with higher dietary GI (291). Molholland et al. conducted a meta-
analysis of 23 cohorts and case-control studies evaluating the associations of GI and risk of 
digestive tract neoplasms. Authors didn’t find any significant association with GI and the different 
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cancer types, although authors stated that there were insufficient data for the majority of the 
types (287). 
 
4.2 Glycemic load 
As stated before, the concept of the GI is based exclusively on the type of carbohydrates 
compounding the food and a fixed amount of available carbohydrates, normally 50 g. The 
quantity restriction was established to provide a food ranking, however, this point can create 
some limitations of daily management in which different carbohydrates amounts are eaten during 
meals. Because this, Walter Willet and colleagues at Harvard defined the GL in 1997 as the 
arithmetic product of GI and carbohydrate amount (264).  
 
Firstly, the physiological validity of the GL concept was questioned due to its mathematical 
conception and the lack of experimental studies evaluating its correlation with glycemic and 
insulinemic responses evoked by different foods. Trying to resolve this, Brand-Miller et al. 
conducted a feeding trial where glycemic and insulinemic responses were measured in healthy 
subjects after the consumption of 10 different foods. The results of this feeding trial 
demonstrated that calculated GL can predict both glycemia and insulinemia (292). However, the 
study has several limitations. First, the participants of the study were healthy lean subjects and 
the obtained results cannot be extrapolated to other populations with associated disease. 
Second, tested foods were only individual foods and the GL ability to predict glycemic and 
insulinemic responses to mixed meals was still unknown. To resolve this second question, the 
group of Professor Brand-Miller conducted a new study a few years after where several individual 
foods and mixed meals were evaluated (293). Again, the results indicated that GL have a better 
prediction of glycemic (92%) and insulinemic (77%) responses of individual foods than 
carbohydrate content. When mixed meals were tested, similar, but lower correlations were found 
between GL and glycemic (76%) and insulinemic (68%) responses.  
 
Ultimately, the validity of GL has been demonstrated with the observational and intervention 
studies where this dietary factor has been associated with disease risk or has been used as dietary 
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tool for prevention or treatment. Several epidemiological studies have been conducted since the 
GL concept was created in 1997. Like GI, GL has been associated with chronic diseases like T2DM, 
obesity, MetS, CVD and cancer (260,262,294–296).   
 
Due to the ability to predict glycemia, GL has been investigated as a dietary factor for the 
prevention of T2DM. Prospective cohort studies have investigated the associations of GL and risk 
of T2DM with inconsistence results (263,264,267,297–306). Some of them found weak or 
contradictory observations (300–306), whereas the others found strong associations (263,267,297–
299). In a meta-analysis including all prospective studies published to date, the authors reported 
a strong and consistently lower risk of T2DM among those subjects consuming low-GL diets. A 
100-g incremental in dietary GL was associated with a 45% (95% CI: 1.31, 1.61, p<0.001) increased 
risk of T2DM in 757984 men and women (294). 
 
CVD have also been directly associated with GL. Epidemiological studies have found a positive 
association between GL and, CHD and stroke, especially in women (278,279,307). Ma et al., found 
a consistent associations between GL and CVD (HR highest vs lowest categories: 1.23; 95% CI: 
1.11–1.36) in a meta-analysis including 229,213 participants and more than 11,363 cases. In a 
stratified analysis, authors found a stronger association among Caucasian women (307). This 
results were supported by a two recent meta-analyses with similar results (278,279), where 
stronger associations were found between GL and CHD, especially in women.   
 
The scientific community has also investigated the associations between GL and cancer, findings 
were similar than those shown previously regarding GI (282–288). GL has also been associated 
with a 21% increased risk of endometrial cancer when higher categories of GL were compared 
with the lowest (287).   
 
4.3 Epidemiological studies 
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As explained previously, GI and GL have been associated with several chronic conditions including 
T2DM, CVD and cancer. However, GI and GL have also been investigated for the prevention and 
treatment of obesity.  
 
Several prospective cohort studies have investigated the link between dietary GI and GL with 
anthropometrical measurements and with an increased risk of obesity (308–319). The most 
investigated measurement is BMI. Several studies have linked both GI and GL with BMI, finding 
inconsistent results (309,313,314,317,319–321). Ma and co-workers were the first in assess the 
associations between the type of carbohydrates and BMI in 572 healthy American adults. BMI was 
found to be positively associated with GI, but not with GL (320). Similar results were found in a 
cohort of 3931 Japanese young adults. Murakami et al found a positive association not only with 
GI and BMI (lowest vs. highest quintiles: 20.8 and 21.2 kg/m2, p for trend =0.03), but also with 
GL (lowest vs. highest quintiles: 20.5 and 21.5 kg/m2, p for trend =0.0005) (319). However, other 
investigators have found inverse (309,313,314) or no (311,317) association between BMI and GI 
or GL. Two studies conducted in Mediterranean population (Spain and Italy) found inverse 
associations between GI/GL and BMI. Mendez and coworkers were the first in report this inverse 
association in 8,195 Spanish adults. After adjusting for total energy intake, mean difference in 
BMI between the highest and lowest GL tertile was -0.71 kg/m2 (p<0.05) for women. No significant 
association was found in men. In a similar analysis, Rossi et al also found an inverse association 
between GL, and also GI, and BMI. Compared with the lowest tertile, the coefficient for the third 
tertile of GI were -0.46 (-0.74, -0.19) among men and -0.81 (-1.13, -0.49) among women.  
Coefficients for GL were -0.79 (-1.14, -0.45) among men and -1.33 (-1.73, -0.94). The same 
authors also analyzed the correlation between GI and GL, and waist-to-hip ratio without 
significant results (313).  GL has also been associated with obesity prevalence in 1078 Korean 
men and women. Those participants in the highest tertile of GL had a 50% less chance to be obese 
compared with those in the lowest (314). 
 
The different types of carbohydrates have also been associated with waist circumference. Four 
different studies have evaluated this association with inconsistent results (310–312,317). Two of 
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the four studies found a positive significant association between GI and waist circumference and 
the other two not (310,317). In a cohort of 89432 participants, aged 20-78 years from five 
European countries, Du and collaborators observed that whit every 10-point higher in GI, waist 
circumference increased by 0.19 cm per year (95% CI: 0.11, 0.27) (311). GI has also been 
associated with a large weight girth in a cohort with 10912 participants from the Cooper Center 
Longitudinal Study. In this study, men and women allocated in the highest quintile of energy-
adjusted GI were associated with a 27% (95% CI: 1.07, 1.51) and 74% (95% CI: 1.04, 2.89) more 
risk of large waist girth prevalence than those allocated in the lowest, respectively. However, 
GL was associated with inversely with large waist girth (OR: 0.52; 95% CI: 0.43, 0.63) in men, but 
not in women. 
 
4.4. Clinical trials 
The usefulness of the GI concept to reduce body weight has been investigated in a large number 
of diverse trails with different length, approximations and populations. The few systematic 
reviews and meta-analysis published to date have found a modest beneficial effect of low-GI 
diets in comparison with high-GI diets or low-fat diets, although there is a significant amount of 
inconsistency in the current findings (260,322). The majority of clinical trials conducted to assess 
the effect of GI/GL on weight loss used a parallel design and compared low-GI/GL diets in 
comparison to either low-fat or high-GI/GL diets.   
 
To our knowledge, from the 26 identified clinical trials, 6 have found a significant beneficial 
effect of GI or GL on weight loss (323–328). One of them is the study conducted by Abete and 
collaborators where 32 participants, 14 females and 18 males, were randomized either to an 
energy-restricted low-GI diet or high-GI diet during 8 weeks. At the end of follow-up, participants 
allocated in the low-GI diet had a significant greater reduction in body weight than the high-GI 
group (−7.5 ± 2.9% vs −5.3 ± 2.6%; p = 0.032, respectively). The rest of clinical trials conducted 
to date couldn’t achieve significant differences between intervention groups although the 
majority of them found a beneficial trend in Low-GI/GL interventions (329–340). Only the study 
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of Bellisle et al. found greater body weight reductions in control group, a Weight Watchers 
POINTS programme for 12 weeks, than the low-GI,high-carbohydrates group.  
 
Three more trails have evaluated the effects of GI on weight loss with a different approximation. 
All three studies were clinical trial with multiple interventions combining GI with other weight-
loss strategies. However, none of them found significant differences between interventions (341–
343).        
 
4.5 Potential mechanisms 
Several physiological mechanisms have been proposed to link dietary GI and body weight or 
obesity. The most accepted are substrate oxidation, satiety and inflammation and they could be 
based on the postprandial metabolic environment precipitated by hyperglycaemia and 
hyperinsulinemia, which accelerate glucose oxidation and stimulate fat storage.  
 
4.5.1 Substrate Oxidation 
Due to postprandial insulin modulation by GI foods, some investigators have assessed the effect 
of GI on fuel partitioning and obesity (344,345). Short-, medium- and long-term studies failed to 
demonstrate that meals or diets differing in GI have significant effects on carbohydrate and fat 
oxidation and body composition. Ritz et al. evaluated fuel oxidation after the ingestion of 50 g 
of carbohydrates from glucose and manioc starch in non-obese healthy subjects for 6 h using a 
crossover design. Cumulative fat oxidation was not different between carbohydrate loads. Díaz 
et al. evaluated the effect of high- and low-glycaemic breakfast and lunch on fuel oxidation in 
obese women using a crossover design. Similarly, no differences between postprandial non-
protein respiratory quotient after breakfast and lunch were observed. Some authors have state 
that probably differences in insulin concentrations between low-GI and high-GI diets are not 
sufficient to modify fuel oxidation.  
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4.5.2 Satiety 
Satiety modulation also appears to be a potential mechanism relating low-GI and weight loss. 
High insulin and low glucagon responses generated after the ingestion of high-GI meal enhances 
glucose uptake in the muscle, liver and fat tissue. Moreover, lipolysis is inhibited and hepatic 
glucose production is limited. This specific metabolic environment, where carbohydrate and fat 
are inhibited in the postprandial state, may lead a quicker hunger responses and lower satiety 
(344). 
 
Short-term satiety has been shown to increase in the vast majority of studies, although results 
have been inconsistent in long-term studies (346–348). Acute clinical trials have evaluated the 
effect of different GI foods or meals at postprandial period with significant results. Arumugan et 
al., conducted an acute clinical trial where they examined the effects of variations in 
postprandial glycemia and insulinemia on subjective satiety in 14 overweight and obese women. 
After 4 hours, participants consuming high-GI beverages indicated significantly higher ratings of 
hunger and prospective intake than those in the low-GI group (349). Similarly, Reynolds and 
coauthors assess the effect of either low or high glycemic meals during all day-long (10 h) on 
blood concentrations of glucose, insulin, cholecystokinin and ghrelin in 12 healthy lean subjects. 
Cholecystokinin concentrations were higher during the initial 7 hours (nearly 60% higer in low-GI 
group than high-GI group, P=0.046), but this effect was not observed at 10 hours (350).  
 
Short/mid-term clinical trials (1-12 weeks) have failed to found significant differences in satiety 
ratings between interventions with different GI (337,351–354). In the study of Alfenas and 
collaborators, 39 healthy adults consumed only low- or only high-GI foods ad libitum in the 
laboratory for 8 days. Glucose and insulin concentrations as well as appetitive sensations were 
determined before and for 2 h following breakfast and lunch on days 1 and 8. There were no 
significant differences in plasma glucose or insulin responses, appetitive ratings, or food intake 
between treatments (352). 
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4.5.3 Inflammation  
Chronic or low-grade inflammation is now considered a key factor in the development of several 
chronic diseases, including T2DM (355) and CVD (356). Also, inflammation rise as an alternative 
mechanism underlying the beneficial effects of low-GI foods on obesity control and its metabolic 
derangements. 
 
Associations between GI/GL and inflammatory markers have been investigated in observational 
studies (301,357–363). The majority of the studies have evaluated the associations of dietary GI 
or GL and hsCRP. Six of the eight studies reported associations confined to either GI or GL were 
related to increased hsCRP (301,357,358,360,361,363). Only the studies of Huffman (362) and 
Murakami (359) found no associations between dietary GI or GL and hsCRP. 
 
Some intervention trails have also evaluated the effect of GI on inflammatory markers, specially 
hsCRP (364–376). Three GI/GL intervention studies reported that reductions in hsCRP (372,375)  
-or IL-6 (369)  -in the low-GI/GL group were significantly larger than changes in the control group. 
In 4 more studies, although no significant effects were found between intervention groups, a 
beneficial trend was observed (364,367,368,374). The rest of the mentioned studies did not found 
significantly greater reductions in hsCRP or IL-6 concentrations in the low-GI/GL group 
(365,366,370,371,373,376). 
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    II. JUSTIFICATION 
 
 
Overweight and obesity are described as one of the major health problems worldwide by the 
WHO. In 2008, it was estimated that more than 1.4 million adults aged between 20 and older 
were overweight and approximately 500 million were obese. 
  
The main reasons for the enormous increase in overweight and obesity are physical inactivity and 
loss of healthy dietary habits. Thus, lifestyle interventions are the principal tool for the 
prevention and treatment of overweight and obesity and its associated comorbidities.  
 
Traditionally, low-fat energy-reduced diets have been recommended for the majority of the 
scientific and medical associations to prevent or treat obesity and its associated CVD risk factors.  
However, nowadays, the potential beneficial role of the dietary carbohydrates, especially the 
quality of those, has been putted into consideration as a valid alternative for the prevention and 
treatment of obesity. The GI concept, introduced in the eighties by Professor Jenkins and 
coworkers, has been postulated as a dietary tool for the management of several chronic diseases 
such as T2DM, CVD, obesity, MetS and cancer. Although strong scientific evidence have been 
published regarding the beneficial effect of GI, and also GL, on the management of T2DM, 
inconsistent results have been shown with other chronic conditions, including obesity and MetS.  
 
Few observational studies have evaluated the cross-sectional associations between GI/GL and 
MetS and its features with inconsistence results. Moreover, the association between GI/GL and 
the incidence of new cases of MetS has never been investigated before. Due to the actual 
inconsistency and the lack of knowledge in the available scientific evidence in the matter of 
GI/GL and MetS, we decided to evaluate this matter in the framework of the PREDIMED study, a 
cohort of individuals at high CVD risk. 
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A low chronic inflammatory status has been pointed out as a key factor involved in the 
pathophysiology of several metabolic diseases. The inflammatory trigger in obesity could be due 
an excess of nutrients. Some investigators have suggested inflammation as one of the possible 
mechanisms linking GI and obesity and its associated comorbidities. In this sense, several 
observational studies have assessed the link between GI and inflammation, although most of 
them have only focused on CRP and were not controlled by potential confounders as fiber. 
 
The scarcity and the inconsistency of the evidence available on the effect of dietary GI and GL 
on adipokines led us to examine the changes in dietary GI and GL and changes in several 
adipokines and related metabolic risk markers of obesity and diabetes in a cohort of elderly 
subjects at high cardiovascular risk. 
 
Finally, due to the limited evidence obtained from prospective observational studies, we have 
aimed to investigate the potential beneficial effects of GI on obesity and its comorbidities in the 
context of a randomized controlled trial. Owing to that we have designed the GLYNDIET study to 
assess the efficacy of two moderate-CH diets and a low-fat diet with different GIs on weight loss 
and the modulation of satiety, inflammation and other metabolic risk markers.
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III. HYPOTHESIS 
 
 
A greater dietary GI and/or GL are associated with an increased risk of MetS development or any 
of its features in a cohort of participants at high cardiovascular risk.  
 
A greater dietary GI and/or GL are associated with higher concentrations of peripheral 
adipokines and inflammatory markers in a cohort of participants at high cardiovascular disease 
risk. 
 
A chronic consumption of low-GI/ low-GL energy restricted diet may be more effective than 
isocaloric high-GI or low-fat diets at reducing body weight and improving metabolic profile, 
through an increased satiety and a beneficial inflammatory modulation.   
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IV. OBJECTIVES 
 
 
To analyze the association between dietary GI and GL and the risk of to develop MetS and its 
features in a high cardiovascular risk population.  
 
To analyze the relationship between dietary GI and GL, peripheral adipokines and inflammatory 
markers in a high cardiovascular risk population   
 
To analyze the effectiveness of a high GI/GL diet versus a low-GI/GL and a low-fat diet in body 
weight loss and the improvement of metabolic profile, through the modulation of some 
mechanisms related to satiety, inflammation and other metabolic risk markers.
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V. METHODS 
 
 
The PREDIMED Study 
The PREDIMED study (Prevención con Dieta Mediterránea) is a large, parallel group, multicenter, 
controlled, randomized clinical trial, aiming to assess the effect of Mediterranean Diet on the 
primary prevention of CVD (myocardial infarction, stroke, and death from cardiovascular causes) 
in elderly subjects at high cardiovascular risk. Secondary end points were death by any cause, 
heart failure with pulmonary edema, new-onset diabetes mellitus, dementia, and cancer 
incidence other than non-melanoma skin cancer. Additionally, other intermediate variables such 
as body weight, blood lipids, blood pressure, fasting glucose and markers of inflammation were 
also evaluated. (www.predimed.org) 
 
Study Population  
Participants were community-dwelling men and women, aged 55–80 and 60–80 years, 
respectively, with no CVD at enrolment and who fulfill the inclusion criteria. The inclusion 
criteria were: 
 
a. Type-2 diabetes. Diagnosis of type-2 diabetes is based on at least one of the following 
criteria: 
 Current treatment with insulin or oral hypoglycemic drugs. 
 Fasting glucose > 126 mg/dl (fasting is defined as no caloric intake at least for 
8 hours). 
 Casual glucose > 200 mg/dl with polyuria, polydipsia, or unexplained weight 
loss. 
 Glucose > 200 mg/dl in two measurements after an oral glucose tolerance test 
OR 
b. Three or more of the following risk factors: 
 current smoker (>1 cig/day during the last month) 
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 HBP (systolic BP>=140 or diastolic BP>=90 mmHg or under antihypertensive 
medication) 
 LDL-cholesterol >= 160 mg/dl 
 HDL-cholesterol <= 40 mg/dl independently of lipid-lowering therapy 
 body mass index >=25 kg/m2 
 family history of premature CHD (definite myocardial infarction or sudden death 
before 55 years in father or male 1st-degree relative, or before 65 years in 
mother or female 1st-degree relative) 
 If the HDL-cholesterol level is >=60 mg/dL, one risk factor should be subtracted. 
 
Major exclusion criteria are: 
 
a. Documented history of previous CVD, including CHD (angina, myocardial infarction, 
coronary revascularization procedures or existence of abnormal Q waves in the 
electrocardiogram (EKG)), stroke (either ischemic or hemorrhagic, including transient 
ischemic attacks), and clinical peripheral artery disease with symptoms of intermittent 
claudication. 
b. Severe medical condition that may impair the ability of the person to participate in a 
nutrition intervention study (e.g. digestive disease with fat intolerance, advanced 
malignancy, or major neurological, psychiatric or endocrine disease). 
c. Any other medical condition thought to limit survival to less than 1 year. 
d. Immunodeficiency or HIV-positive status. 
e. Illegal drug use or chronic alcoholism or total daily alcohol intake >80 g/d. 
f. Body mass index > 40 kg/m2. 
g. Difficulties or major inconvenience to change dietary habits. 
h. Impossibility to follow a Mediterranean-type diet, for religious reasons or due to the 
presence of disorders of chewing or swallowing (e.g., difficulties to consume nuts) 
i. A low predicted likelihood to change dietary habits according to the Prochaska and 
DiClemente stages of change model (377). 
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j. History of food allergy with hypersensitivity to any of the components of olive oil or nuts. 
k. Participation in any drug trial or use of any investigational drug within the last year. 
l. Institutionalized patients for chronic care, those who lack autonomy, are unable to walk, 
lack a stable address, or are unable to attend visits in the PCC every 3 months. 
m. Illiteracy. 
n. Patients with an acute infection or inflammation (e.g., pneumonia) are allowed to 
participate in the study 3 months after the resolution of their condition. 
 
Subjects were recruited from October 2003 to June 2009 in the different recruitment centers all 
around Spain (Málaga, Sevilla, Balearic Island, Barcelona, Reus‐Tarragona, Pamplona, Basque 
Country, Valencia, Gran Canaria). 
 
Intervention 
The participants included in the study were randomly assigned in a 1:1:1 ratio to one of three 
nutritional education interventions: a Mediterranean diet supplemented with extra-virgin olive 
oil (approximately 1 litre per week), a Mediterranean diet supplemented with 30g of mixed nuts 
(15g of walnuts, 7.5 g of hazelnuts and 7.5 of almonds), or a control group in which participants 
received counselling to follow a low-fat diet according to the Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of 
High Blood Cholesterol in Adults (Adult Treatment Panel III) (378). The dietary intervention was 
conducted by registered dietitians who advised and encouraged the study participants to follow 
the assigned intervention diet. After two screening visits, participants who were randomized in 
one of the three intervention diets had an individual baseline visit and a group session. Every 
three month, group sessions were scheduled separately for every intervention diet where 
participants were provided with written material including shopping lists, weekly meal plans and 
cooking recipes, and supplemental foods at no cost for those participants allocated to the 
Mediterranean diets. Olive oil and nut industry companies are committed to supplying for free 
the food supplements used in the study. Yearly, general medical questionnaire (Appendix 1), 
including cardiovascular risk factors; past medical history; pharmacological treatment; family 
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history of ischemic cardiopathy, hypertension and diabetes; tobacco use; alcohol intake and 
socioeconomic status, and food frequency questionnaire (FFQ) (Appendix 2) were obtained. 
 
Dietary assessment 
At baseline and annually thereafter, a validated 137-item FFQ was administrated to estimate 
average daily nutrient intake over the previous 12-month period (379). The FFQ was designed to 
be semi-quantitative and the frequencies of consumption of the food items were reported on an 
incremental scale with nine levels (never or almost never, 1–3 times per month, once per week, 
2–4 times per week, 5–6 times per week, once per d, 2–3 times per d, 4–6 times per d and more 
than six times per d). Energy and nutrient intake was calculated from Spanish food composition 
tables (380,381).  
 
With glucose as a reference scale, GI values for each food were extracted from the international 
GI and GL values (382).  The average daily dietary GI was calculated by multiplying the GI of 
individual foods by the percentage of total energy contributed by carbohydrate (∑[GI food item 
× (g carbohydrate per serving food item × servings consumed per day/g carbohydrate consumed 
per day)]). Dietary GL was calculated by multiplying the daily GI of each food by the amount of 
carbohydrate consumed and dividing the product by 100((daily GI × g carbohydrate consumed per 
day)/100), and then adding up the values for all foods (257,383). The FFQ was validated for 
dietary GI and GL. Reproducibility and relative validity for dietary GI explored by the intraclass 
correlation coefficient was 0.321 and 0.244, respectively, and 0.846 and 0.525 for dietary GL. 
 
A yearly 14-item questionnaire was the primary measure used in this study to appraise adherence 
of participants to the Mediterranean diet (Appendix 3). Mediterranean Diet Adherence 
questionnaire was adapted from a previous questionnaire from a Spanish case-control study for 
myocardial infraction (384). In addition to the 9 initial items from the original questionnaire 
(385), 5 extra items were added to assess adherence to the traditional Mediterranean diet foods 
and cooking habits. 
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Anthropometric and biochemical measurements 
Anthropometric measurements and blood pressure were measured at baseline and every year 
during the follow-up. Body weight and height were measured wearing light clothing and no shoes 
by trained personal with calibrated scales and wall-mounted stadiometer, respectively. Waist 
circumference was measured with an anthropometric tape midway between the lower rib and 
the superior border of the iliac crest.  Blood pressure was measured in triplicate with a 5-min 
interval between each measurement with a validated semiautomatic oscillometer (Omron HEM-
705CP, Hoofddorp, Netherlands).  
 
Leisure-time physical activity was evaluated using the validated Spanish version of the Minnesota 
leisure-time physical activity questionnaire (386) (Appendix 4).  
 
At baseline and yearly, blood samples were obtained in fasting conditions and aliquots were kept 
frozen (-80ºC) in a Biobank. Plasma glucose, serum cholesterol, HLD cholesterol, and triglycerides 
concentrations were determined using standard enzymatic automated methods. In patients 
whose triglycerides were less than 400 mg/dl, LDL-cholesterol concentrations were estimated 
using Friedewald formula (387). 
 
Peripheral adipokines and inflammatory markers were determined in 511 consecutively admitted 
participants recruited from the PREDIMED trial centers in Reus and Barcelona. Plasma 
adiponectin, adipsin, ghrelin, glucagon-like peptide 1 (GLP-1), glucose-dependent insulinotropic 
polypeptide (GIP), IL-6, leptine, plasminogen activatior inhibitor-1 (PAI-1), resistin, TNF-α and 
visfatin were determined using the Bio-Plex cytokine assay (Bio-Rad Laboratories Inc., Hercules, 
CA, USA) according to manufacturer’s instructions. 
Metabolic Syndrome definition 
Prevalent MetS and its features were defined in accordance with the updated harmonized 
International Diabetes Federation and the American Heart Association/National Heart, Lung, and 
Blood Institute criteria (152).  Participants were considered to have MetS if they had three or 
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more of the following components: a) abdominal obesity for European individuals (≥88 cm and 
≥102cm in women and men, respectively), b) hypertriglyceridemia [≥150 g/dL] or drug treatment 
for elevated TG, c) low concentrations of HDL-cholesterol [<40 mg/dL in men; <50 mg/dL in 
women] or drug treatment for low HDL-cholesterol, d) high blood pressure (systolic ≥130 and/or 
diastolic ≥85 mmHg) or antihypertensive drug treatment, e) high fasting glucose [≥100 mg/dL] or 
drug treatment for diabetes. 
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The GLYNDIET study. 
The GLYNDIET study has been designed as a 6-month randomized, parallel, controlled clinical 
trial aiming to evaluate the effect of the dietary GI on weight loss, satiety, glucose and insulin 
metabolism, lipid profile, inflammation and other emergent metabolic risk markers. 
 
Study Population 
Eligible participants were community-dwelling men and women aged between 30 and 60 years, 
with a BMI between 27 and 35 Kg/m2. 
 
Participants were excluded if they had one of the following criteria:  
 
a. Non-controlled T2DM defined as a HbA1c > 8%.  
b. Systolic blood pressure (SBP) > 159 mmHg or diastolic blood pressure (DBP) > 99 mmHg. 
c. Plasma LDL-cholesterol > 160 mg/dL. 
d. Plasma triglyceride concentrations > 400 mg/dL. 
e. Suspicion of secondary obesity 
f. Presence of any inflammatory or chronic obst.ructive pulmonary disease, infection, 
active neoplastic, endocrine or haematological disease at the time of the study. 
g. Blood leukocyte count ≥ 11 x 106 cells. 
h. Use of anti-inflammatory drugs, steroids, hormones or antibiotics that could affect the 
parameters analysed in the study. 
i. Changes in medication for lipid profile, diabetes or hypertension in the previous three 
months. 
j. Active alcoholism or drug dependence, excluding tobacco use. 
k. Restrictive diet 3 months before the study or weight loss > 5 kg in the previous 3 months. 
l. Any medical condition that advised against being included in the study. 
m. Problems in understanding the study or anticipated difficulty in making dietary changes 
according to the Prochaska and DiClemente model (377). 
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Subjects were recruited from the outpatient clinics in obesity of the University Hospital of Sant 
Joan de Reus and announcements made in the Reus (Spain) primary care centres of the Institut 
Català de la Salut. 
 
Intervention 
Participants fulfilling the inclusion criteria were randomly assigned to three different dietary 
intervention groups of the same size. Randomization was done by a computer-generated random-
number sequence. Subjects were assigned to blocks of 3 participants balanced for sex, age (<45 
and ≥ 45 years) and anti-diabetic medication use (yes or no). Subjects were advising on a: a low-
GI diet (40% of energy from fat, 42% from low-GI carbohydrates and 18% from protein), a high-GI 
diet (40% of energy from fat, 42% from high-GI carbohydrates and 18% from protein) or a low-fat 
diet (30% of energy from fat, 52% from high-GI carbohydrates and 18% from protein). 
Recommended diets were isocaloric, and the amount of dietary fibre, do not differ between the 
three intervention groups. Diets were designed at 1500, 1700, 2000 and 2500 kcal/d, and all 
participants were categorized as having one of the four levels of dietary energy content after 
subtracting 500 kcal/d of the total estimated energy intake to achieve a desired weight loss. 
 
Anthropometric and biochemical measurements 
Clinical visits were scheduled at baseline, 15 days into the intervention, and then monthly until 
the end of the study. Body weight and height were measured using calibrated scales and a wall-
mounted stadiometer, with subjects wearing light clothes and no shoes. Waist circumference 
was measured twice midway between the lowest rib and the iliac crest. Body composition was 
measured by bio-electrical impedance analysis (TANITA TBF-300, Arlington Heights, USA). Blood 
pressure was measured in the non-dominant arm, using a validated semiautomatic oscillometer 
(Omron HEM-705CP, Hoofddorp, Netherlands) in duplicate with a five-minute interval between 
each measurement. Physical activity was evaluated using the validated Spanish version of the 
Minnesota Leisure Time Physical Activity Questionnaire (24). Blood samples were collected at 
baseline and at the end of the study and were kept frozen (-80ºC) in a Biobank. Routine 
biochemical measurements were determined using standard enzymatic automated methods 
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(COBAS, Roche Diagnostics Limited, Basel, Switzerland). Specific biochemical measurements 
were determined in plasma using enzyme-linked immunosorbent assay commercial kits and 
MILLIPLEX® MAP Plex Kit (Merck Millipore, Billerica, USA). Insulin resistance and insulin secretion 
were estimated by the HOMA-IR and HOMA-BCF methods (388). 
 
Dietary assessment 
Dietary intake was estimated at baseline and in the 1st, 3rd and 6th months of intervention by 
means of 3-day dietary records including two workdays and a weekend day. Energy and nutrient 
intake were calculated using Spanish food composition tables (389).  
 
Visual analogue scales (VASs)  
At baseline, a fixed breakfast test, according to the nutritional characteristics of the intervention 
assigned diets, was served to all subjects. VASs were evaluated in a fasted state (immediately 
before the breakfast) and every thirty minutes after for a period of 2 hours in a controlled 
environment. 
 
Full details of the GLYNDIET study protocol are detailed in the publication nº1. 
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VI. STUDY POPULATION 
 
Study 1. Dietary glycemic index/load and peripheral adipokines and inflammatory markers in 
elderly subjects at high cardiovascular risk. 
 
Subjects in the analysis were 511 consecutively admitted participants recruited from the 
PREDIMED trial centers in Reus and Barcelona. 
 
 
 
Study 2. Effect of the glycemic index of the diet on weight loss, modulation of satiety, 
inflammation and other metabolic risk factors: a randomized controlled trial. 
 
For the present study, all participants of the GLYNDIET study, recruited between February 2010 
and May 2012, were analyzed. 
 
 
 
Study 3. Dietary glycemic index and glycemic load are positively associated with risk of 
developing metabolic syndrome. 
 
The total sample considered for the cross-sectional analysis was 6,622 participants, whereas for 
the longitudinal assessment contained only those subjects free of MetS at baseline (n=1832). 
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Authors: Martí Juanola-Falgarona, Núria Ibarrola-Jurado, Jordi Salas-Salvadó, Antoni Rabassa-
Soler, Mònica Bulló. 
 
Year: 2013 
Journal: Nutrición Hospitalaria 
Volume: 28 
Pages: 382-390 
 
Abstract: 
 
BACKGROUND: GI and/or GL have been explored as an alternative for the prevention and/or 
management of obesity, cardiovascular disease, type 2 diabetes mellitus, and cancer. Objective: 
The purpose of the manuscript is to describe the design and methods used in the GLYNDIET 
Project, a study designed to simultaneously address the questions related to the exactly role of 
low glycaemic index carbohydrates has on weight loss. 
 
METHODS: This study was designed as a 6-months randomized, parallel, controlled clinical trial 
aiming to evaluate the effect of the dietary GI on weightloss, satiety, glucose and insulin 
metabolism, lipid profile, inflammation and other emergent metabolic risk markers. Eligible 
subjects were community-dwelling men and women aged between 30 and 60 years, with a BMI 
between 27 and 35 kg/m2. Subjects were randomly assigned to three different dietary 
intervention groups (low-GI diet, high-GI diet or low-fat diet), that were isocaloric, and did not 
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differ in the amount of dietary fibre. Monthly, study subjects were scheduled for control visits 
where anthropometry, blood pressure, dietary habits, satiety and physical activity were 
assessed. Blood, urine and subcutaneous adipose tissue samples were collected at baseline and 
at the end of the study to further molecular and biochemical measurements. 
 
DISCUSSION: The GLYNDIET study was designed to determine if there is a greater effectiveness 
of a carbohydrate restricted diet with low-GI compared to an isocaloric diet with carbohydrates 
of high-GI or low-fat diet on weight loss in middle long-term.
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Publication 2. 
 
Title: Dietary glycemic index/load and peripheral adipokines and inflammatory markers in 
elderly subjects at high cardiovascular risk. 
 
Authors: Mònica Bulló, Rosa Casas, María del Puy Portillo, Josep Basora, Ramón Estruch,  Ana 
García-Arellano, Arrate Lasa, Martí Juanola-Falgarona, Fernando Arós, Jordi Salas-Salvadó. 
 
Year: 2013 
Journal: Nutrition, Metabolism and Cardiovascular Disease 
Volume: 23 
Pages: 443- 450 
 
Abstract: 
 
BACKGROUND AND AIMS: Epidemiological and clinical studies suggest that low-GI diets could 
protect against weight gain. However, the relationship between these diets and adipokines or 
inflammatory markers is unclear. In the present study we examine how the dietary GI and dietary 
GL are associated with several adipokines and related metabolic risk markers of obesity and 
diabetes in a cross-sectional and longitudinal manner. 
 
METHODS AND RESULTS: 511 elderly community-dwelling men and women at high cardiovascular 
risk were recruited for the PREDIMED trial. Dietary data were collected at baseline and after 1 
year of follow-up. The GI and GL were calculated. Plasma leptin, adiponectin and other metabolic 
risk markers were measured at baseline and after 1 year. At baseline, subjects in the highest 
quartiles of GI showed significantly higher levels of TNF and IL-6 than those in the lowest 
quartiles. Dietary GI index was negatively related to plasma leptin and adiponectin levels. After 
1 year of follow-up, subjects with a higher increase in dietary GI or GL showed a greater reduction 
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in leptin and adiponectin plasma levels. There was no association between GI or GL and the other 
metabolic markers measured. 
 
CONCLUSION: Our results suggest that the consumption of high-GI or high-GL diets may modulate 
plasma concentrations of leptin and adiponectin, both adipostatic molecules implicated in energy 
balance and cardiometabolic risk.  
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Publication 3. 
 
Title: Effect of the glycemic index of the diet on weight loss, modulation of satiety, 
inflammation and other metabolic risk factors: a randomized controlled trial. 
 
Authors: Martí Juanola-Falgarona, Jordi Salas-Salvadó, Núria Ibarrola-Jurado, Antoni Rabassa-
Soler, Andrés Díaz-López, Marta Guasch-Ferré, Pablo Hernández-Alonso, Rafael Balanza, Mònica 
Bulló. 
 
Year: 2014 
Journal: American Journal of Clinical Nutrition 
Volume: 100 
Pages: 27-35 
 
Abstract: 
 
BACKGROUND: Low–GI diets have been proven to have beneficial effects in such chronic 
conditions as type 2 diabetes, coronary heart disease, and some types of cancer, but the effect 
of low-GI diets on weight loss, satiety, and inflammation is still controversial. 
 
OBJECTIVE: We assessed the efficacy of 2 moderate-carbohydrate diets and a low-fat diet with 
different GIs on weight loss and the modulation of satiety, inflammation, and other metabolic 
risk markers. 
 
DESIGN: The GLYNDIET study is a 6-mo randomized, parallel, controlled, clinical trial conducted 
in 122 overweight and obese adults. Participants were randomly assigned to one of the following 
3 isocaloric energy-restricted diets for 6 mo: 1) a moderate-carbohydrate and high-GI diet (HGI), 
2) a moderate-carbohydrate and low-GI diet (LGI), and 3) a low-fat and high-GI diet (LF). 
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RESULTS: At weeks 16 and 20 and the end of the intervention, changes in body mass index (BMI; 
in kg/m2) differed significantly between intervention groups. Reductions in BMI were greater in 
the LGI group than in the LF group, whereas in the HGI group, reductions in BMI did not differ 
significantly from those in the other 2 groups (LGI: 22.45 6 0.27; HGI: 22.30 6 0.27; LF: 21.43 6 
0.27; F = 4.616, P = 0.012; pairwise comparisons: LGI compared with HGI, P = 1.000; LGI compared 
with LF, P = 0.016; HGI compared with LF, P = 0.061). The decrease in fasting insulin, homeostatic 
model assessment of insulin resistance, and homeostatic model assessment of b cell function was 
also significantly greater in the LGI group than in the LF group (P , 0.05). Despite this tendency 
for a greater improvement with a low-GI diet, the 3 intervention groups were not observed to 
have different effects on hunger, satiety, lipid profiles, or other inflammatory and metabolic risk 
markers. 
 
CONCLUSION: A low-GI and energy-restricted diet containing moderate amounts of carbohydrates 
may be more effective than a high-GI and low-fat diet at reducing body weight and controlling 
glucose and insulin metabolism. This trial was registered at Current Controlled Trials 
(www.controlled-trials.com) as ISRCTN54971867.
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Publication 4. 
 
Title: Dietary glycemic index and glycemic load are positively associated with risk of 
developing metabolic syndrome. 
 
Authors: Martí Juanola-Falgarona, Jordi Salas-Salvadó, Pilar Buil-Cosiales, Dolors Corella, Ramón 
Estruch, Emili Ros, Montserrat Fitó, Fernando Arós, Enrique Gómez-Gracia, Miquel Fiol, José 
Lapetra, Rosa Maria Lamuela-Raventós, Lluis Serra-Majem, Xavier Pintó, Miguel Ángel Muñoz, 
Valentina Ruiz-Gutiérrez, J. Alfredo Martínez,  Itandehui Castro-Quezada, Mònica Bulló on behalf 
of the PREDIMED Study Investigators. 
 
Year: 2014 
Journal: Journal of Nutrition 
Volume:  
Pages:  
 
Abstract: 
 
BACKGROUND/OBJECTIVES: The MetS is a cluster of metabolic abnormalities that have been 
associated with an increased risk of cardiovascular disease. The aim of the present study was to 
evaluate how the GI and GL are associated with MetS and its features. 
 
SUBJECTS/METHODS: A prospective cohort analysis was conducted in 6,622 participants from the 
PREDIMED study. Energy and nutrient intakes were evaluated using a validated 137-item food 
frequency questionnaire. Dietary GI and GL were calculated using the international GI and GL 
values. MetS and its features were defined in accordance with the criteria of the American Heart 
Association/National Heart, Lung, and Blood Institute (AHA/NHLBI). 
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RESULTS: In a cross-sectional analysis, a positive association was observed across tertiles of GI 
and MetS, abdominal obesity, hypertriglyceridemia, low HDL-cholesterol and high blood pressure 
features among non-diabetic participants (P for trend < 0.05) while no relationship was found 
between tertiles or the continuous variables of dietary GI or GL at baseline and the prevalence 
of MetS or any of its features among diabetic participants. During the median follow-up of 4.8 
years, subjects in the third tertile of change in GI and GL have a greater risk of developing MetS 
than those in the first tertile (Hazard Ratio: 1.19, 95% CI: 1.01–1.40, P for trend= 0.05; Hazard 
Ratio: 1.23, 95% CI: 1.03–1.48, P for trend= 0.070) independently of the presence of diabetes. 
Changes in dietary GI were also associated with an increased risk of low HDL-cholesterol and high 
blood pressure MetS fe                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            
zatures. Changes in dietary GL were also associated with an increased risk of abdominal obesity, 
hypertriglyceridemia and low HDL-cholesterol.   
 
CONCLUSIONS: Our results suggest that both dietary GI and GL have a potential role in the 
development of MetS and associated clinical features in subjects at high cardiovascular risk. 
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VIII. DISCUSSION 
 
The research undertaken for this thesis aimed to investigate the possible role of the GI on 
reducing risk of chronic diseases, focusing on  the development of MetS and its features and the 
effects of GI on weight loss and its potential mechanisms, especially chronic inflammation. The 
potential role of GI or GL in the development of MetS and its features was investigated in the 
PREDMIED study, a cohort of Mediterranean subjects at high CVD risk. The relationship between 
GI/GL and markers of inflammation were also assessed in a prospective epidemiologic study 
carried out in the PREDIMED cohort. Finally, the effects of GI and GL on weight loss have been 
evaluated in a 6-month randomized controlled trial where the participants were allocated in one 
of the three intervention energy-restricted diets. Additionally in the same RCT, potential 
mechanisms linking GI and weight loss were also evaluated, especially effects on systemic 
inflammation and satiety. The findings presented in the current thesis contribute to extent the 
knowledge of the beneficial effects of GI and GL in the management and development of some 
chronic diseases.   
 
8.1 Associations between dietary GI or GL and metabolic syndrome 
In the current prospective analysis conducted in the PREDIMED cohort, we have shown for the 
first time that an increase in dietary GI and GL during the follow-up was associated with a reduced 
risk of MetS development and also some of some of its features, including hypertriglyceridemia, 
abdominal obesity and lower HDL-cholesterol components of the MetS. This results support 
previous evidence linking the intake of high-GI or high-GL foods with a higher risk of CVD risk 
factors such as MetS. 
 
Current scientific evidence linking dietary GI and GL and disease risk is large and non-conclusive. 
Few studies have evaluated the cross-sectional associations between overall dietary GI or GL and 
MetS (295,310,312,316) with inconsistent results. Whereas two of them found a significant 
positive association between GI or GL and MetS prevalence (295,312), the other two reported no 
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significant associations (310,316). Our results showed a significant positive association between 
GI and GL, and prevalence of MetS among non-diabetic participants. However, we have also 
observed, for the first time, a direct relationship between changes in GI and GL and an increased 
risk of MetS incidence, suggesting a causal relationship between carbohydrate quality and MetS 
development.  
 
Abdominal obesity is one of the main features of the MetS and has been identified as an 
independent risk factor for several chronic conditions such as T2DM, CVD and cancer. GI has been 
investigated as a preventive nutritional strategy or treatment of body weight management and 
fat distribution. To date, contradictory results have been published regarding the possible 
beneficial effect of GI on weight loss. Whereas a significant weight-loss related to low-GI diets 
was observed in short-term clinical trials (322), no beneficial effects were observed in the long 
term (390), and these diets have not been included in the nutritional recommendations of the 
European Food Safety Authority in the context of obesity treatment (391). Contradictory results 
have also been reported regarding abdominal obesity. Within the observational studies analyzing 
the associations between GI/GL and abdominal obesity, few of them found non-significant results 
(310,316), whereas others found a positive relationship (311,312,315). The results of a huge 
observational study conducted in 89,432 participants from 5 different European countries showed 
a significant increase of 0.26 cm of waist circumference per year for a 10-unit increase in GI 
(311). Additionally, a recent meta-analysis of randomized clinical trials with a follow-up of at 
least 6 month reported no significant effect of GI/GL on waist circumference (390). In the present 
study, non-diabetic participants in the highest GI tertile showed a large waist girth, thus 
contributing to the higher prevalence of MetS observed. Accordingly, in the longitudinal 
assessment the higher risk of developing abdominal obesity observed in those participants who 
increased their GL during the follow-up reinforces the potentially negative effect of these diets 
on such an important metabolic cardiovascular factor as abdominal obesity.  
 
In agreement with previous findings (392–394), we also found a significant association between 
the highest GI tertile and blood pressure in non-diabetic subjects. Moreover, we found that the 
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risk of developing hypertension increased with the increase in GI during the follow-up and a trend 
with increased GL at the limit of statistical significance. These longitudinal results support those 
published by Philippou et al. who reported significantly higher reductions in 24-h blood pressure 
after a 6-month low GI diet in comparison to a high-GI diet (394). This may be because increased 
insulin resistance, plasma cholesterol and abdominal obesity, all features of the MetS, act 
directly on the arterial wall (395) and as potential mediators of sodium retention and volume 
expansion thus increasing both blood pressure (166,167) and inflammation, and affecting the 
oxide nitric system (396). 
 
High dietary GI or GL have also been associated with lower concentrations of HDL-cholesterol 
and increased levels of tryglycerides (397–399). In a cross-sectional study of more than 18,000 
non-diabetic middle-aged and older women, those in the highest quintiles of both GI and GL 
showed lower HDL-cholesterol levels and significantly higher TG concentrations (399).  Frost et 
al., also reported similar results in a cohort of British subjects (398). However, in a recent meta-
analysis of randomized clinical trials with at least a 6-month follow-up, GI/GL were not observed 
to have a significant effect on HDL-cholesterol levels (390). In our study, we also found a positive 
association between GI or GL and low HDL-cholesterol and hypertriglyceridemia in non-diabetic 
subjects. Moreover, subjects who increased their dietary GI or GL during the follow-up also 
showed a greater risk of developing hypertriglyceridemia or having lower HDL-cholesterol. This 
could be attributed to a lower clearance of both liver and intestinally derived triacylglycerol 
remnants described after high GI meals (400). 
 
Regarding fasting glucose levels, there is a great consensus about the beneficial role of low-GI 
carbohydrate diets on the management of type 2 diabetes. However, the glucose and insulin 
downregulating role attributed to low-GI or GL diets is still controversial. In a recent meta-
analysis of 14 long-term RCT comparing low GI/GL versus high GI/GL diets, fasting insulin 
concentrations reduced more in participants following low-GI diets, whereas no significant 
changes were found for fasting glucose and glycosilated hemoglobin (390). Accordingly, in the 
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present analysis, we failed to find any significant association between GI or GL and the 
component of the MetS related to glucose levels. 
 
8.2 Associations between GI and GL, and chronic inflammation. 
The results of the cross-sectional analysis conducted in 511 elderly subjects show an inverse 
association between plasma leptin and adiponectin concentrations, and dietary GI and GL. 
Furthermore, in a prospective longitudinal assessment after a 1-year follow-up we demonstrated 
an inverse association between an increased dietary GI or GL and changes in both plasma leptin 
and adiponectin levels, independently of potential dietary and non-dietary confounders. 
However, no significant relationships were observed between dietary GI or GL and other 
adipokine metabolic markers analyzed. 
 
It is quite clear that energy homeostasis requires a fine regulation of food intake, nutrient 
absorption, energy expenditure and storage. These processes are coordinated by the central 
nervous system after controlling the homeostatic signals derived from peripheral tissues. Since 
leptin discovered, the secretory activities of adipose tissue have increased exponentially with 
more than 50 adipocyte-derived products that make different contributions to obesity and its 
pathophysiological features (401). Therefore, because a low grade of chronic inflammation is 
now recognized as one of the central mechanisms underlying obesity and associated 
comorbidities, the potential effect of dietary GI and GL on inflammatory modulation seems 
relevant. However, the few studies carried out to date are controversial because they focus on 
the plasma C-reactive protein and do not evaluate the long-term effects of GI or GL on adipostats 
or other adipokines related to obesity and comorbidities (364,402). 
 
The results of our 1-year prospective longitudinal study conducted in a large sample of subjects 
at high cardiovascular risk are in agreement with the adipostatic theory. The adipokines, leptin 
and adiponectin, are considered to be the two major adipostats in humans because of their role 
in the central nervous system and in peripheral tissues (403,404). In our study, we have 
demonstrated that an increase in the dietary GI and GL are associated with a decrease in leptin 
UNIVERSITAT ROVIRA I VIRGILI 
GLYCEMIC INDEX IN THE MANAGEMENT OF OBESITY AND METABOLIC SYNDROME. 
Martí Juanola Falgarona 
Dipòsit Legal: T 1610-2015
Discussion- 112 
 
and adiponectin plasma concentrations. Our results are in agreement with those obtained using 
an intervention study conducted in rats fed with a high-GI starch diet for 12 weeks  (405) and 
those reported in a postprandial state (406). Therefore, if we consider that higher leptin levels 
are associated with a decrease in food intake and an increase in energy expenditure acting at 
the hypothalamic central level (407), the down-regulation of leptin induced by an increase in GI 
or GL observed in our study could be considered as a mechanism favoring the weight gain and 
obesity attributed to high-GI diets. Moreover, because leptin also exerts autocrine or paracrine 
actions increasing lipolysis and decreasing lipogenesis, the decrease in circulating plasma leptin 
levels observed in our study may lead to a decrease in fatty-acid oxidation and an increase in 
glucose oxidation, which favors fat deposition. Finally, because leptin is primarily known as a 
satiety factor, the decrease in plasma leptin after a high-GI diet sustained the concept that these 
diets are less satiating than low-GI diets (408). 
 
Adiponectin is the most abundant adipocytokine in humans. A low level of circulating adiponectin 
results in insulin resistance, glucose intolerance, dyslipidemia and atherosclerosis (409). 
Recently, adiponectin has been identified in the cerebrospinal fluid of rodents suggesting that it 
has an important role in the central regulation of energy intake and energy expenditure (410). 
However, although the central effects of adiponectin on energy balance are still unclear and 
controversial in humans (404) the results of our study support the hypothesis that high-GI-induced 
hypoadiponectinemia could be to the detriment of obesity. Moreover, the hypoadiponectinemia 
induced by the increase in dietary GI that we observed and reported in a previous epidemiologic 
study  (411) could partly explain the relationship between the GI of the diet and the increased 
risk of T2DM and CVD associated with the consumption of this type of diet. 
 
In our study, we failed to show that the GI and GL had any relationship with incretins, other 
adipokines or related molecules. We only observed significantly higher levels of TNF and a trend 
to higher levels of IL-6 in those subjects in the higher GI quartiles, after adjusting for 
confounders, suggesting that pro-inflammatory cytokines worsened in those subjects consuming 
high-GI foods. In a longitudinal manner, we also reported a positive relationship between an 
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increase in GL and an increase in GIP, but not GLP-1, thus suggesting that a high dietary GL 
contributes to fat deposition and obesity. 
 
8.3. Effect of GI or GL on weight loss 
To our knowledge, this is the first study to simultaneously evaluate the effectiveness of 
moderate-carbohydrate LGI, moderate-carbohydrate HGI, and LF diets with weight loss as the 
main outcome. The results presented in the present thesis showed that a LGI diet reduced weight 
more effectively than did a traditional LF diet, with a HGI. 
 
To date, nearly thirty studies have evaluated the effects of GI or GL on weight management with 
inconsistent results (323–327,412). A meta-analysis with 6 of the previously mentioned RCT found 
a beneficial effect of LGI diets. With a total of 202 participants and a duration between 5 weeks 
and 6 months, the results of the combined RCT showed that participants randomized in the LGI 
interventions lost -1.1 kg (95%CI -2.0 to -0.2) more than those allocated in the HGI group (413). 
However, the RCTs used in the meta-analysis did not adjust intervention for potential dietary 
confounders such as protein or total fiber. However these results are not supported by those 
published in an another meta-analysis conducted by Schwingshackl et al. Including 15 long-term 
(between 12 to 24 months) RCTs, the results of this meta-analysis showed no beneficial effects 
of the LGI diets on body weight or waist circumference in comparison with the HGI diets (390). 
The results from our RCT showed that those participants in the LGI or HGI lost more weight than 
those in the traditional LGI diet, although significant differences were only found between LGI 
and LF groups. These results suggest that diets rich in vegetable fat, mainly extra-virgin olive oil, 
and moderate amounts of carbohydrates have a greater effect on obesity management than 
traditional LF diets. Although we didn’t observed a significant effect of the GI, significant 
differences in weight loss were observed between those diets with larger differences in GL, 
indicating that maybe is the combination of quality and quantity of carbohydrates a key point in 
the management of obesity. These results are not supported by those showed in the publication 
nº 2 where those non-diabetic subjects with higher dietary GI were more likely to have abdominal 
obesity and also with those participants with higher increases in dietary GL during the follow-up 
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that had a 38% more risk of large waist circumference. This discrepancies observed between the 
two studies can be explained by the differences in the design of the studies and also by 
differences between populations.  
 
In the present study no differences were observed between diets in satiety or hunger rates 
derived from VASs, suggesting that the effect on body weight of low- or high-GI diets is mediated 
by other mechanisms rather than short-term satiety modulation. Despite this, and in line with 
the results of short-term satiety studies (346), we observed a non-significant tendency to higher 
satiety rates and lower hunger rates in the LGI group than in the other groups. With the results 
of observed in the publication nº 3, where changes in dietary GI and GL were associated with 
changes in leptin concentrations, we speculated that maybe this relationship could partly explain 
the observed beneficial effects of low-GI foods on satiety. However, these results do not support 
those observed from the VASs.  
 
Insulin sensitivity has been thought to have an important association with the effectiveness of GI 
on weight change (414). However, the reports on the effect of dietary GI/GL on glucose and 
insulin metabolism provide inconsistent data. The results of a recent systematic review and meta-
analysis of RTCs showed no significant effects of diets with different GI or GL on fasting glucose 
and HbA1c. However, the same meta-analysis showed that LGI diets had a significantly greater 
effect on fasting insulin than HGI diets (390). In the GLYNDIET study, both insulin sensitivity and 
resistance significantly improved in participants in the LGI group even after adjusting by changes 
in body weight, suggesting additional mechanisms linking GI/GL and insulin metabolism rather 
than body weight reduction. Improvements in glycemia and insulinemia attributable to LGI diets 
could be mediated by changes in the incretin axis. In this regard, a 28-day weight-maintaining 
high-GL controlled diet led to significantly lower post-prandial concentrations of GLP-1 than a 
low-GL diet after a test breakfast (415). The results of our study support a long-term effect of 
GI on the incretin axis. However, the significant decrease in GIP-1 circulating levels observed in 
the HGI group cannot explain the higher decrease of glucose levels observed in the same dietary 
intervention group. The results observed in the PREDIMED cohort are not in line with those 
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observed in the GLYNDIET study, probably because of differences in the design, methodology and 
population studied. Further research is needed to understand the exact long-term effect of GI/GL 
on incretin axis and its implication in obesity and T2DM. Due to the postulated effect of both 
osteocalcin and uncarboxylated osteocalcin forms on insulin resistance (416), the slightly higher 
increase in osteocalcin and uncarboxylated osteocalcin in the LGI diet group than in the HGI or 
LF diet groups observed in our study reinforces the beneficial role that this type of diet plays in 
insulin metabolism. Overall, our results are in line with those of a previous meta-analysis (414) 
and support findings from prospective cohort studies that consistently indicate that consumption 
of lower GI are associated with a lower T2DM risk (294).  
 
As expected, we observed that HDL-cholesterol tended to increase and triglycerides slightly 
decrease, although the differences observed between groups were non-significant. These results 
are in line with those observed in the publication nº 2 where changes in dietary GI and GL were 
associated with an increased risk of low-HDL-cholesterol and hypertriglyceridemia. Although no 
significant differences were observed between groups in the GLYNDIET study, the results 
presented here add more evidence to the current knowledge of the beneficial effects of GI on 
lipid profile and CVD risk factors.  
 
As commented before, inflammatory modulation has also been postulated as a potential 
mechanism linking dietary GI/GL with the management of obesity and its related comorbidities. 
Few clinical trials have evaluated the effect of GI/GL on inflammatory markers and most of those 
that have only focus on the CRP (369,371,372,383,417). In 773 obese adults from the DIOGENES 
trial, changes in CRP were significantly greater in the LGI than the HGI groups (372). Decreased 
IL-6, TNF, PAI-1 and leptin concentrations have also been observed after weight loss induced 
by LF or LGI hypocaloric diets with no between-group differences (418). Our results from the 
PREDIMED study also indicate a positive associations between GI and GL and some inflammatory 
markers such leptin or adiponectin. However, in the GLYNDIET study, subjects allocated to the 
LGI group show a significant reduction in peripheral CRP and leptin concentrations, and a 
tendency to a higher decrease in IL-6 after the intervention. However, the changes were shown 
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to be different between intervention groups. In our study, the GI/GL of the diet was not observed 
to have any effect on the other inflammatory markers analyzed although, as expected, most of 
them tend to improve because of the weight loss in all the intervention groups. 
 
8.4 Strengths and Limitations 
 
The major strengths of the current thesis are: 
 
The results from the PREDIMED study were analyzed in a cross-sectional and longitudinal manner 
in a large cohort of individuals, indicating both association and cause-relationship. 
 
The strengths of the GLYNDIET study are its medium-term duration, the randomized design 
balanced in each intervention group for sex, age and use of T2DM drugs, and the differences 
between diets in relation to the GI and GL. Moreover, our study is the first to simultaneously 
analyze the effect of an LGI, an HGI and an LF diet on weight loss, satiety, glucose and insulin 
metabolism and several associated metabolic risk markers. 
 
However we recognize that this thesis does have several limitations that need to be taken into 
account.  
 
First, the results analyzed in the PREDIMED cohort were conducted in adult population who are 
at high cardiovascular risk. Thus, baseline concentrations of metabolic markers used in this thesis 
were higher than general population and more prone to be modulated by the dietary 
intervention. Because of that, the results cannot be generalized to other populations. 
 
Second, there may be some dietary measurement error. The FFQ used to collect the dietary data 
was not designed to assess dietary GI and dietary GL. However, after validation, we concluded 
that the GL data collected by the FFQ was more accurate than the GI data. Moreover, due to 
scarcity of data, it was necessary to use GI values derived from studies conducted in different 
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countries where the food or its properties may differ from that consumed in Spain. Nevertheless, 
these limitations would also apply to some other epidemiologic studies and clinical trials involving 
GI and GL measurements. 
 
Third, the results analyzed in the PREDIMED study were conducted in a cohort that was 
undergoing nutritional interventions and we cannot discount a residual effect of intervention 
diets on the present results. However, to address this limitation and to minimize the effect, we 
have adjusted all longitudinal analyses for the intervention group. 
 
Finaly, in the GLYNDIET study, we used dietary food records during the follow up as an indirect 
marker of dietary compliance. Lack of specific biochemical markers of dietary compliance 
related to GI/GL is also a limitation of the study.  
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IX. CONCLUSIONS 
 
To analyze the association between dietary GI and GL and the risk of to develop MetS and its 
features in a high cardiovascular risk population. 
 
Our results suggest that both dietary GI and GL have a potential role in the development of MetS 
and some of its components in a cohort of Mediterranean subjects at high cardiovascular risk.  
 
To analyze the relationship between dietary GI and GL, peripheral adipokines and inflammatory 
markers in a high cardiovascular risk population. 
 
The consumption of diets with high-GI foods or high dietary GL may modulate plasma 
concentrations of some cardiometabolic markers thus contributing to weight gain and 
cardiovascular disease. 
 
To analyze the effectiveness of a high GI/GL diet versus a low-GI/GL and a low-fat diet in body 
weight loss and the improvement of metabolic profile, through the modulation of some 
mechanisms related to satiety, inflammation and other metabolic risk markers. 
 
A moderate-CH low-GI diet may be more effective for weight loss than a moderate-CH high-GI 
diet or a conventional low-fat diet. The metabolic benefits observed for insulin resistance and 
sensitivity in those subjects following a low-GI diet, and the tendency to improve other 
inflammatory and associated metabolic risk markers, also indicate that low-GI diets are better 
tools for managing obesity and its associated comorbidities.
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